WO2024051937A1 - Method for assessing efficacy of treatment protocols for neurodegenerative diseases - Google Patents
Method for assessing efficacy of treatment protocols for neurodegenerative diseases Download PDFInfo
- Publication number
- WO2024051937A1 WO2024051937A1 PCT/EP2022/074901 EP2022074901W WO2024051937A1 WO 2024051937 A1 WO2024051937 A1 WO 2024051937A1 EP 2022074901 W EP2022074901 W EP 2022074901W WO 2024051937 A1 WO2024051937 A1 WO 2024051937A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- seq
- beta
- proteolytic
- proteins
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 108
- 238000000034 method Methods 0.000 title claims abstract description 105
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 71
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 71
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 183
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 143
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 23
- 238000003745 diagnosis Methods 0.000 claims abstract description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 163
- 108090000623 proteins and genes Proteins 0.000 claims description 163
- 235000018102 proteins Nutrition 0.000 claims description 153
- 239000000523 sample Substances 0.000 claims description 76
- 101710190189 Cerebral dopamine neurotrophic factor Proteins 0.000 claims description 65
- 102100035345 Cerebral dopamine neurotrophic factor Human genes 0.000 claims description 65
- 239000008194 pharmaceutical composition Substances 0.000 claims description 57
- 208000018737 Parkinson disease Diseases 0.000 claims description 56
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 48
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 48
- 239000003900 neurotrophic factor Substances 0.000 claims description 48
- 102000035195 Peptidases Human genes 0.000 claims description 30
- 108091005804 Peptidases Proteins 0.000 claims description 30
- 102100035889 Vacuolar protein sorting-associated protein 16 homolog Human genes 0.000 claims description 29
- 239000004365 Protease Substances 0.000 claims description 28
- 102100028951 Protein MTSS 1 Human genes 0.000 claims description 28
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 24
- 108010087195 Contactin 1 Proteins 0.000 claims description 22
- 102100024326 Contactin-1 Human genes 0.000 claims description 22
- 102100029505 E3 ubiquitin-protein ligase TRIM33 Human genes 0.000 claims description 22
- 102100037583 FAST kinase domain-containing protein 5, mitochondrial Human genes 0.000 claims description 22
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 22
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 22
- 102100021833 Mesencephalic astrocyte-derived neurotrophic factor Human genes 0.000 claims description 22
- 101710155665 Mesencephalic astrocyte-derived neurotrophic factor Proteins 0.000 claims description 22
- 238000003556 assay Methods 0.000 claims description 22
- 102100040055 Amyloid beta precursor like protein 1 Human genes 0.000 claims description 21
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 claims description 21
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 claims description 21
- 108010038447 Chromogranin A Proteins 0.000 claims description 21
- 102000010792 Chromogranin A Human genes 0.000 claims description 21
- 101710164884 E3 ubiquitin-protein ligase TRIM33 Proteins 0.000 claims description 21
- 101710130270 FAST kinase domain-containing protein 5, mitochondrial Proteins 0.000 claims description 21
- 102100036197 Prosaposin Human genes 0.000 claims description 21
- 101710152403 Prosaposin Proteins 0.000 claims description 21
- 102000010208 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 claims description 21
- 108050001894 Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 claims description 21
- 101710168919 Amyloid beta precursor like protein 1 Proteins 0.000 claims description 20
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 19
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 19
- 102100034619 Neural proliferation differentiation and control protein 1 Human genes 0.000 claims description 19
- 101710136904 Neural proliferation differentiation and control protein 1 Proteins 0.000 claims description 19
- 102100023057 Neurofilament light polypeptide Human genes 0.000 claims description 18
- 102100023846 Peptidyl-prolyl cis-trans isomerase FKBP3 Human genes 0.000 claims description 18
- 102100032442 Protein S100-A8 Human genes 0.000 claims description 18
- 108010090677 neurofilament protein L Proteins 0.000 claims description 18
- 102000003908 Cathepsin D Human genes 0.000 claims description 17
- 108090000258 Cathepsin D Proteins 0.000 claims description 17
- 102000009333 Apolipoprotein D Human genes 0.000 claims description 16
- 108010025614 Apolipoproteins D Proteins 0.000 claims description 16
- 101710131188 Autophagy protein 13 Proteins 0.000 claims description 16
- 102000004072 Beclin-1 Human genes 0.000 claims description 16
- 108090000524 Beclin-1 Proteins 0.000 claims description 16
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 claims description 16
- 108050007957 Cadherin Proteins 0.000 claims description 16
- 102000000905 Cadherin Human genes 0.000 claims description 16
- 102000016938 Catalase Human genes 0.000 claims description 16
- 108010053835 Catalase Proteins 0.000 claims description 16
- 108010075016 Ceruloplasmin Proteins 0.000 claims description 16
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 16
- 108010066813 Chitinase-3-Like Protein 1 Proteins 0.000 claims description 16
- 102000018704 Chitinase-3-Like Protein 1 Human genes 0.000 claims description 16
- 102000003780 Clusterin Human genes 0.000 claims description 16
- 108090000197 Clusterin Proteins 0.000 claims description 16
- 102100039499 E3 ubiquitin-protein ligase RNF26 Human genes 0.000 claims description 16
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims description 16
- 102100034866 Kallikrein-6 Human genes 0.000 claims description 16
- 101710176224 Kallikrein-6 Proteins 0.000 claims description 16
- 102100039648 Lactadherin Human genes 0.000 claims description 16
- 102100028263 Limbic system-associated membrane protein Human genes 0.000 claims description 16
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 16
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 claims description 16
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 claims description 16
- 101710116808 Neural cell adhesion molecule 2 Proteins 0.000 claims description 16
- 102100030467 Neural cell adhesion molecule 2 Human genes 0.000 claims description 16
- 102100021582 Neurexin-1-beta Human genes 0.000 claims description 16
- 101710147149 Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 claims description 16
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 claims description 16
- 101710156987 Protein S100-A8 Proteins 0.000 claims description 16
- 102100032420 Protein S100-A9 Human genes 0.000 claims description 16
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 16
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 16
- 102100033846 Transmembrane protein 126A Human genes 0.000 claims description 16
- 101710169834 Transmembrane protein 126A Proteins 0.000 claims description 16
- 108060000864 flotillin Proteins 0.000 claims description 16
- 102000010660 flotillin Human genes 0.000 claims description 16
- 108010038347 neurexin Ibeta Proteins 0.000 claims description 16
- 108060008004 synaptotagmin Proteins 0.000 claims description 16
- 102000003137 synaptotagmin Human genes 0.000 claims description 16
- 102000017304 72kDa type IV collagenases Human genes 0.000 claims description 15
- 108050005269 72kDa type IV collagenases Proteins 0.000 claims description 15
- 101710151528 Beta-hexosaminidase subunit beta Proteins 0.000 claims description 15
- 108010028780 Complement C3 Proteins 0.000 claims description 15
- 102000016918 Complement C3 Human genes 0.000 claims description 15
- 101710109182 E3 ubiquitin-protein ligase RNF26 Proteins 0.000 claims description 15
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims description 15
- 102100023364 Ganglioside GM2 activator Human genes 0.000 claims description 15
- 101710201362 Ganglioside GM2 activator Proteins 0.000 claims description 15
- 101000878213 Homo sapiens Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Proteins 0.000 claims description 15
- 101000990908 Homo sapiens Neutrophil collagenase Proteins 0.000 claims description 15
- 101000782382 Homo sapiens Vacuolar protein sorting-associated protein 16 homolog Proteins 0.000 claims description 15
- 102100036984 Inactive peptidyl-prolyl cis-trans isomerase FKBP6 Human genes 0.000 claims description 15
- 101710191666 Lactadherin Proteins 0.000 claims description 15
- 108010051335 Lipocalin-2 Proteins 0.000 claims description 15
- 102000013519 Lipocalin-2 Human genes 0.000 claims description 15
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims description 15
- 102100030411 Neutrophil collagenase Human genes 0.000 claims description 15
- 102000056189 Neutrophil collagenases Human genes 0.000 claims description 15
- 108030001564 Neutrophil collagenases Proteins 0.000 claims description 15
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 claims description 15
- 101710147152 Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 claims description 15
- 108010020062 Peptidylprolyl Isomerase Proteins 0.000 claims description 15
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 claims description 15
- 101710156990 Protein S100-A9 Proteins 0.000 claims description 15
- 102100036352 Protein disulfide-isomerase Human genes 0.000 claims description 15
- 102000004338 Transferrin Human genes 0.000 claims description 15
- 108090000901 Transferrin Proteins 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 108010059830 limbic system-associated membrane protein Proteins 0.000 claims description 15
- 108020003519 protein disulfide isomerase Proteins 0.000 claims description 15
- 101000986265 Homo sapiens Protein MTSS 1 Proteins 0.000 claims description 14
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 14
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 14
- 101710152661 Protein MTSS 1 Proteins 0.000 claims description 14
- 101710176097 Vacuolar protein sorting-associated protein 16 homolog Proteins 0.000 claims description 14
- 230000002438 mitochondrial effect Effects 0.000 claims description 13
- 101710143255 Apoptosis-inducing factor 1 Proteins 0.000 claims description 12
- 239000012472 biological sample Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 108090000631 Trypsin Proteins 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 8
- 238000011519 second-line treatment Methods 0.000 claims description 7
- 239000012588 trypsin Substances 0.000 claims description 7
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 102100040124 Apoptosis-inducing factor 1, mitochondrial Human genes 0.000 claims description 4
- 102000035101 Aspartic proteases Human genes 0.000 claims description 4
- 108091005502 Aspartic proteases Proteins 0.000 claims description 4
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 4
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 4
- 108091005503 Glutamic proteases Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000012479 Serine Proteases Human genes 0.000 claims description 4
- 108010022999 Serine Proteases Proteins 0.000 claims description 4
- 108091005501 Threonine proteases Proteins 0.000 claims description 4
- 102000035100 Threonine proteases Human genes 0.000 claims description 4
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 4
- 101710186947 Apoptosis-inducing factor 1, mitochondrial Proteins 0.000 claims description 3
- 208000015872 Gaucher disease Diseases 0.000 claims description 3
- 230000002132 lysosomal effect Effects 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 210000003722 extracellular fluid Anatomy 0.000 claims description 2
- 208000010544 human prion disease Diseases 0.000 claims description 2
- 230000000642 iatrogenic effect Effects 0.000 claims description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 2
- 210000004880 lymph fluid Anatomy 0.000 claims description 2
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 208000008864 scrapie Diseases 0.000 claims description 2
- 210000001138 tear Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 description 85
- 239000003814 drug Substances 0.000 description 61
- 229940079593 drug Drugs 0.000 description 60
- 238000012360 testing method Methods 0.000 description 59
- 102000004196 processed proteins & peptides Human genes 0.000 description 47
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 34
- 230000007423 decrease Effects 0.000 description 24
- 230000000875 corresponding effect Effects 0.000 description 21
- 230000008859 change Effects 0.000 description 16
- 235000019419 proteases Nutrition 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 102400000267 Rhomboid-related protein 2, N-terminal fragment Human genes 0.000 description 10
- 101800000645 Rhomboid-related protein 2, N-terminal fragment Proteins 0.000 description 10
- 101800000716 Tumor necrosis factor, membrane form Proteins 0.000 description 10
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 7
- 238000002552 multiple reaction monitoring Methods 0.000 description 7
- 238000013517 stratification Methods 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 239000000544 cholinesterase inhibitor Substances 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 230000012447 hatching Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019833 protease Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100023513 Flotillin-2 Human genes 0.000 description 2
- 101000737775 Homo sapiens Cerebral dopamine neurotrophic factor Proteins 0.000 description 2
- 101000827313 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
- 229960002802 bromocriptine Drugs 0.000 description 2
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 2
- 229960004596 cabergoline Drugs 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000000688 desorption electrospray ionisation Methods 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 102000054128 human CDNF Human genes 0.000 description 2
- 229950005862 lazabemide Drugs 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical group C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 229960004640 memantine Drugs 0.000 description 2
- JZXRLKWWVNUZRB-UHFFFAOYSA-N n-(2-aminoethyl)-5-chloropyridine-2-carboxamide Chemical compound NCCNC(=O)C1=CC=C(Cl)C=N1 JZXRLKWWVNUZRB-UHFFFAOYSA-N 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 229960004851 pergolide Drugs 0.000 description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
- 229960003089 pramipexole Drugs 0.000 description 2
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 2
- 238000012910 preclinical development Methods 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 2
- 229960000245 rasagiline Drugs 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- 229960001879 ropinirole Drugs 0.000 description 2
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 2
- 229960003179 rotigotine Drugs 0.000 description 2
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 2
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 2
- 229960003946 selegiline Drugs 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108090000066 Adenain Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108091005504 Asparagine peptide lyases Proteins 0.000 description 1
- 108090000432 Aspergillopepsin II Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102000004178 Cathepsin E Human genes 0.000 description 1
- 108090000611 Cathepsin E Proteins 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000012192 Cystatin C Human genes 0.000 description 1
- 108010061642 Cystatin C Proteins 0.000 description 1
- 102100036898 Desumoylating isopeptidase 1 Human genes 0.000 description 1
- 101710152189 Desumoylating isopeptidase 1 Proteins 0.000 description 1
- 102100036966 Dipeptidyl aminopeptidase-like protein 6 Human genes 0.000 description 1
- 108700033317 EC 3.4.23.12 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102100021023 Gamma-glutamyl hydrolase Human genes 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000890407 Homo sapiens Amyloid beta precursor like protein 1 Proteins 0.000 description 1
- 101000890622 Homo sapiens Apoptosis-inducing factor 1, mitochondrial Proteins 0.000 description 1
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 description 1
- 101000804935 Homo sapiens Dipeptidyl aminopeptidase-like protein 6 Proteins 0.000 description 1
- 101001103590 Homo sapiens E3 ubiquitin-protein ligase RNF26 Proteins 0.000 description 1
- 101000634991 Homo sapiens E3 ubiquitin-protein ligase TRIM33 Proteins 0.000 description 1
- 101001028241 Homo sapiens FAST kinase domain-containing protein 5, mitochondrial Proteins 0.000 description 1
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 description 1
- 101001034314 Homo sapiens Lactadherin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101710162762 Limbic system-associated membrane protein Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 108010009254 Lysosomal-Associated Membrane Protein 1 Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 101710088428 Napsin-A Proteins 0.000 description 1
- 102100027343 Napsin-A Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101800000980 Protease nsP2 Proteins 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000033866 Rare inborn errors of metabolism Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010080085 Scytalidium lignicolum acid proteases Proteins 0.000 description 1
- 108050008729 Scytalidoglutamic peptidases Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- IRXRGVFLQOSHOH-UHFFFAOYSA-L dipotassium;oxalate Chemical compound [K+].[K+].[O-]C(=O)C([O-])=O IRXRGVFLQOSHOH-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 description 1
- 108010050322 glutamate acetyltransferase Proteins 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229940127022 high-dose drug Drugs 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- 238000005173 quadrupole mass spectroscopy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 108090000250 sortase A Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 108010067247 tacrolimus binding protein 4 Proteins 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Definitions
- the present invention relates to a method for assessing the efficacy of protocols for the treatment of neurodegenerative diseases using a multiplexed targeted proteomics-based assay.
- Neurodegenerative diseases are a heterogeneous group of conditions that are characterised by the progressive degeneration of the function and structure of the peripheral nervous system or the central nervous system (CNS).
- the effective treatment of such diseases is increasingly important since the prevalence of the conditions is increasing in many countries.
- One route to study the course of treatment for such diseases is to look at biomarkers that can be obtained readily in biological samples from patients (Heywood et al., Molecular Neurodegeneration, 10, 64 (2015)).
- the present invention provides a method for assessing the efficacy of a treatment protocol for a neurodegenerative disease using a multiplexed targeted proteomics assay.
- the biomarkers are obtained from cerebrospinal fluid (CSF).
- CSF cerebrospinal fluid
- a method for assessing the efficacy of a treatment for a neurodegenerative disease in a subject comprising:
- step (ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in T able 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- a proteolytic peptide of at least one protein selected from the group of proteins as shown in T able 1 said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- Complement C3 Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-
- the treatment for the neurodegenerative disease may comprise the administration of a pharmaceutical composition comprising a pharmaceutically active substance.
- the administration of the pharmaceutical composition may be part of a prescribed course of treatment or a clinical trial.
- the pharmaceutical composition may be administered once a day, twice a day, once a week, once a month, or at other frequencies according to the course of treatment prescribed or the clinical trial protocol.
- the clinical trial may be for one month, two months, 6-months or 12 months.
- the pharmaceutical composition may comprise one or more neurotrophic factors (NTF) and/or one or more proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- the CDNF may comprise recombinant human CDNF.
- the CDNF may be administered using a neurosurgically implanted drug delivery system.
- the CDNF may be administered by intermittent bilateral intraputamenal infusions.
- the pharmaceutical composition may be administered, for example, once a month.
- the efficacy of a treatment may be a measure of the effectiveness of any generally suitable method treatment for the neurodegenerative disease.
- the efficacy may be expressed in terms of the presence or absence of one or more clinical symptoms or one or more sideeffects of the pharmaceutical composition used to treat the subject.
- the efficacy of a treatment may also therefore be correlated with a change in the concentration of a protein biomarker in a sample comprising a protein as shown in Table 1.
- the change in the concentration of a relevant biomarker as defined herein may be an increase in concentration of a biomarker or a decrease in concentration of a biomarker compared to a baseline or control value for such a biomarker.
- Absolute peptide concentration may be compared across a set of proteins in a sample.
- the samples may be collected at different time intervals from the start of treatment regime (i.e. time at Week 0 (“Week zero”).
- Subsequent samples may be collected from patients at approximately Week 20 and/or Week 45.
- the results for the samples obtained at different time points can then be normalised to a baseline and the results can be expressed as relative change from the baseline. For example, a 1.5-fold peptide concentration increase or 0.67-fold concentration decrease from baseline in drug treated groups whilst having no or lesser corresponding peptide alteration in the placebo group may be considered to indicate drug treatment efficacy for a pharmaceutical composition comprising a drug under assessment according to a method of the invention.
- Subsequent samples may be collected from patients at approximately Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 or 30 and/or Week 35, 40, 45, 50, 55 or 60.
- Subsequent samples may be collected from patients at approximately month 1 , 2, 3, 4, 5 or 6 and/or month 7, 8, 9, 10, 11 or 12. Subsequent samples may be collected from patients at approximately six-month intervals. Subsequent samples may be collected from patients at approximately month 6 and/or month 12.
- An at least 1.5-fold peptide concentration increase and/or an at least 0.67-fold concentration decrease from baseline in drug treated groups whilst having no or lesser corresponding peptide alteration in the placebo group may be considered to indicate drug treatment efficacy for a pharmaceutical composition comprising a drug under assessment according to a method of the invention.
- the neurodegenerative disease may be selected from the group consisting of Parkinson’s Disease, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Batten disease or a transmissible spongiform encephalopathy (e.g. scrapie, bovine spongiform encephalopathy (BSE) or Creutzfeldt-Jakob disease (CJD), (including iatrogenic, variant, familial or sporadic forms of CJD), or a lysosomal neurodegenerative disorder (e.g. Gaucher’s disease).
- the neurodegenerative disease may be Parkinson’s Disease.
- the first aspect of the invention may comprise a method for assessing the efficacy of a treatment for Parkinson’s disease in a subject, wherein the treatment comprises the administration of a pharmaceutical composition comprising CDNF.
- the methods of the present invention may be applicable to a broad range of other neurodegenerative conditions, such as Alzheimer’s disease, and other disease that have a neurodegenerative component, for instance rare diseases/inborn errors of metabolism/lysosomal storage disorders etc.
- the test according to a method of the invention may also applicable to inflammatory conditions, for instance Cystatin C in kidney diseases.
- the sample may be cerebrospinal fluid (CSF), blood (serum, whole blood (venous blood or peripheral blood), plasma, urine, tear, saliva, interstitial fluid, lymph fluid or tissue samples.
- CSF cerebrospinal fluid
- the sample may be collected by any suitable means including collection of CSF by lumbar puncture, venous blood collection by direct removal from a vein or potentially via a finger prick blood collection device or a bloodspot card or plasma spot card.
- the same proteins may also be measured using a different technology platform.
- ELISA, SIMOA, Clink, Western Blot, or other immunoassay platforms may be used to the measure the same protein set.
- Aptamers oligonucleotide or peptide molecules that bind to a specific target molecule
- sample types may be used for this test.
- biofluid samples such as serum, plasma with its different sample additives (anticoagulants) may be suitable.
- the protease may be a serine protease (e.g. trypsin, chymotrypsin, thrombin, elastase, or subtilisin), a cysteine protease (e.g.
- pepsin e.g. scytalidoglutamic peptidase (eqolisin), aspergilloglutamic peptidase), a metalloprotease (e.g. an ADAM or a matrix metalloproteinase), or an asparagine peptide lyase.
- the protease may be trypsin.
- a proteolytic peptide is therefore a peptide sequence from a protein which has been produced by the action of a protease cleaving a peptide bond between amino acids in the protein sequence.
- Such proteolytic peptides are therefore oligopeptides being formed of a number of amino acids.
- the proteolytic peptide may be from 5 to 30 amino acid residues in length, suitably 6 to 20 amino acids in length, 7 to 25 amino acids in length, or any of 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids in length.
- a proteolytic peptide prepared by the action of the protease trypsin on a protein may be referred to as a tryptic peptide and so on.
- the proteolytic peptide may suitably have a sequence as set out in Table 1.
- the method of the invention may comprise assaying for the presence of up to all 50 proteins in Table 1 with respect to a proteolytic peptide thereof.
- the method of the invention may comprise assaying for the presence of a proteolytic peptide of at least 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45 or 50 proteins as shown in Table 1.
- the methods of the invention therefore comprise the assaying for up to 118 proteolytic peptides of the 50 proteins shown in Table 1.
- the method of the invention may comprise assaying for at least 5 to 10, 5 to 15, 5 to 20, 5 to 25, 5 to 30, 5 to 35, 5 to 40, 5 to 45 or 5 to 50 proteolytic peptides of Table 1.
- the number of proteolytic peptides assayed for is at least 5, at least 15, at least 20 or at least 25 proteolytic peptides as shown in Table 1.
- the number of proteolytic peptides assayed for may be 48 proteolytic peptides as shown in Table 1.
- the proteolytic peptides may be one proteolytic peptide of each protein of Table 1 except for Protein MTSS 1 (Metastasis suppressor YGL-1) and Lymphocyte cytosolic protein 2.
- the method can be said to comprise assaying the proteolytic digest of proteins of step (i) for the presence of a panel of proteolytic peptides of at least two proteins selected from the group of proteins as shown in Table 1.
- the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a panel of proteolytic peptides of at least 48 proteins, wherein the 48 proteins are:
- MMP9 Matrix metalloproteinase-9 (MMP9) Chitinase-3-like protein 1 (CHI3L1) Protein S100-A8 (S100A8) Protein S100-A9 (S100A9) Neutrophil collagenase (MMP8) Complement C3 (C3) Galectin-3-binding protein (LGALS3BP)
- PSAP Prosaposin
- Beta-hexosaminidase subunit beta (HEXB)
- CSD Cathepsin D
- Lysosome-associated membrane glycoprotein 1 (LAMP1)
- FAST kinase domain-containing protein 5 FASTKD5
- AIFM1 Apoptosis-inducing factor 1, mitochondrial
- Transmembrane protein 126A (TMEM126A)
- NDL Neurofilament light polypeptide
- Chromogranin-A (CHGA)
- Apolipoprotein E (APOE)
- Apolipoprotein D (APOD)
- NCAM2 Neural cell adhesion molecule 2
- Amyloid-beta precursor protein APP
- Amyloid-like protein 1 (APLP1)
- FKBP3 Peptidyl-prolyl cis-trans isomerase FKBP3
- FKBP4 Peptidyl-prolyl cis-trans isomerase FKBP4
- PDIA1 Protein disulfide-isomerase A1
- LSAMP Limbic system-associated membrane protein
- VPS16 Vacuolar protein sorting-associated protein 16 homolog VPS16
- Peptidyl-prolyl cis-trans isomerase PPIase; HEL-S-39
- Lactadherin MFGE8
- MMP2 72 kDa type IV collagenase
- TGFBI Transforming growth factor-beta-induced protein ig-h3
- NPDC1 Neural proliferation differentiation and control protein 1
- GM2A Ganglioside GM2 activator
- Table 1 shows 50 proteins differentially expressed in Parkinson’s Disease patients following drug treatment and corresponding 118 proteolytic peptide sequences with corresponding heavy isotope-labelled peptide internal standard sequences.
- the methods of the invention may comprise Table 1 also shows haemoglobin subunit beta as an optional suitable analytical control protein with corresponding proteolytic peptide sequence and corresponding heavy isotope-labelled peptide internal standard sequence.
- An internal standard sequence may not be required in order to analyse the expression of any given protein according to a method of the invention.
- a single protein internal standard can be used for the entire biomarker test, e.g. yeast enolase without any heavy isotopelabelled internal standards.
- Other heavy isotope-labelled internal standards having a similar retention time can be used for quantification of peptides which do not have their own internal standards.
- targeted proteomics methods which use no internal standards at all, for example the University College Dublin test for prostate cancer.
- the method of the invention may suitably comprise assaying for the six proteolytic peptides in the following group of proteins and corresponding proteolytic peptides:
- the at least one protein may be selected from the group consisting of Chromogranin-A, Amyloid-beta Precursor Protein, Amyloid-like Protein 1 , Transforming Growth Factor-Beta- Induced Protein IG-H3, Prosaposin and Apolipoprotein E.
- the at least one protein may be selected from the group consisting of Chromogranin-A, Amyloid-beta Precursor Protein, Amyloid-like Protein 1 , Transforming Growth Factor-Beta-Induced Protein IG-H3 and Prosaposin.
- proteolytic peptide of at least one protein may be selected from the group consisting of:
- AATVGSLAGQPLQER (SEQ ID No. 64).
- proteolytic peptide of at least one protein may be selected from the group consisting of:
- GDELADSALEIFK SEQ ID No. 114
- QEILAALEK SEQ ID No. 23
- the at least one protein is Chromogranin-A and the proteolytic peptide of the at least one protein is SGELEQEEER (SEQ ID No. 52).
- the at least one protein is Amyloid-beta Precursor Protein and the proteolytic peptide of the at least one protein is QQLVETHMAR (SEQ ID No. 78).
- the at least one protein is Amyloid-like Protein 1 and the proteolytic peptide of the at least one protein is QMYPELQIAR (SEQ ID No. 85).
- the internal standard may be QMYPELQIAR(U-13C6,15N4)VEQAT (SEQ ID No. 162).
- the at least one protein is Transforming Growth Factor- Beta- Induced Protein IG-H3 and the proteolytic peptide of the at least one protein is GDELADSALEIFK (SEQ ID No. 114).
- the at least one protein is Prosaposin and the proteolytic peptide of the at least one protein is QEILAALEK (SEQ ID No. 23).
- the internal standard may be QEILAALEK(U-13C6,15N2)GCSFL (SEQ ID No. 132).
- the at least one protein is Apolipoprotein E and the proteolytic peptide of the at least one protein is AATVGSLAGQPLQER (SEQ ID No. 64).
- the internal standard may be AATVGSAGQPLQER(U-13C6,15N4)AQAWG (SEQ ID No. 151).
- the methods of the present invention use mass spectrometry to identify the concentrations of the peptides, for example proteolytic peptides having the sequences as set out in Table 1 .
- MS mass spectrometry
- the proteolytic peptides are injected into the MS system where the proteolytic peptides are first detected as intact peptides and then subsequently fragmented into smaller pieces which may be termed peptide fragments.
- the methods of the present invention provide for the detection of up to 118 proteolytic peptides of the up to 50 proteins as shown in Table 1.
- the concentrations of the peptides may be used to assess the efficacy of a treatment for a neurodegenerative disease and/or to stratify a subject having a neurodegenerative disease, with reference to a calibration curve of the concentrations for known reference proteolytic peptides.
- the concentrations of the proteolytic peptides assayed for in the samples are therefore linked with assessing the efficacy of a treatment for a neurodegenerative disease and/or stratifying a subject having a neurodegenerative disease.
- a difference in proteolytic peptide concentration from a control indicates efficacy of a treatment for a neurodegenerative disease and/or stratifying a subject having a neurodegenerative disease.
- the control may be a baseline control.
- the control may be a placebo group.
- the concentrations of the proteolytic peptides may be normalised to the control. Concentrations may be expressed as fold changes relative to the control, such as fold changes from baseline.
- the methods of the invention may further account for whether the proteolytic peptides are shown herein to be up-regulated or downregulated.
- Biomarker levels across different patients groups may be different; i.e. increased or decreased relative to another group (such as a control or a placebo).
- a combination of biomarkers may be used to separate patient groups based on biomarker concentration and using a principal component analysis (PCA) or fold change differences. Fold change differences may be used to separate patient groups using a threshold or cut-off point, for example as illustrated Figures 6 & 7.
- PCA principal component analysis
- Reference peptides may be used to pre-configure the mass spectrometer prior to use in a method of the invention to detect and quantitate the concentration of peptides of Table 1 in a sample.
- the reference peptides also allow for the construction of calibration lines with each batch of samples tested in order to ensure robust results.
- Heavy isotope-labelled peptides may be used as internal standards to control analytical variability in each sample and also provide for calibration lines.
- a mass spectrometry platform is used to measure the concentration of the analytes. Whilst triple quadrupole mass spectrometry platforms, operated in MRM mode, are preferred for this test, there could be other mass spectrometry platforms or other data acquisition modes used to design around this test.
- One example is high resolution mass spectrometry platforms (e.g. Sciex 6600, Thermo Orbitrap or Waters QTOF-type instruments) where “pseudo” MRM or PRM modes could be used for measurements.
- Triple quadrupole instruments are more robust and provide more reproducible data and thus other platforms may not reach the same performance in all aspects of the test.
- Peptide ionisation interface/method prior to mass spectrometry analysis could also be different.
- the test is designed to use electrospray ionisation (ESI), however the peptides can be ionised using matrix-assisted laser desorption/ionization (MALDI) or desorption electrospray ionization (DESI) or atmospheric-pressure chemical ionization (APCI) or other ionisation methods.
- MALDI matrix-assisted laser desorption/ionization
- DESI desorption electrospray ionization
- APCI atmospheric-pressure chemical ionization
- the test is designed to use heavy isotope-labelled internal standards for accurate measurements, however differently labelled or unlabelled peptide or protein internal standards could be used which may or may not meet the performance of heavy isotopelabelled standards.
- the method may comprise determining the relative concentration of the proteolytic peptide measured in the sample.
- the relative concentration of a peptide measured in the sample may refer to the concentration of the proteolytic peptide relative to the corresponding labelled and/or unlabelled reference proteolytic peptide.
- test of the present invention may be multiplexed with another test measuring proteins in a biological sample, e.g. CSF proteins, with the same technology platform.
- the test of the present invention may be a part of a larger test. If other treatment efficacy tests emerge, the test of the present invention could be used to augment such other tests to enhance overall performance.
- the proteins from which the peptide sequences are derived are set out in Table 1 described herein.
- the method of the present invention may be a multiplexed assay.
- a different peptide set to that shown in Table 1 could also be measured from the same proteins as shown in Table 1 using the same targeted proteomics platform but using a different protease.
- the examples of the present invention described herein show one embodiment of a method of the invention, however different peptides from the same set of 50 proteins may be used. This includes peptides generated using the same protease as in this test (trypsin) or different proteases (LysC, GluC etc).
- the mass spectrometry analysis of peptides is liquid chromatography- targeted mass spectrometry (LC-MS) using triple quadrupole instruments, operated in timed multiple reaction monitoring (MRM) mode.
- LC-MS liquid chromatography- targeted mass spectrometry
- MRM timed multiple reaction monitoring
- the methods of the present invention therefore comprise the use of targeted proteomics.
- the technique comprises the quantification of specific, pre-selected proteins or proteolytic peptides from a given sample and requires a pre-existing understanding of disease biology to guide protein selection.
- the technique is therefore distinct from discovery proteomics which seeks to gather information about all proteins and proteolytic peptides in a sample without pre-existing knowledge/hypotheses around disease biology. Internal standards or calibration lines for every protein or peptide of interest are not and cannot be used in discovery proteomics.
- Discovery proteomics is also conducted using different instrument operation modes, e.g. SWATH, HDMSE etc comparted to MRM or PRM in targeted proteomics. Data processing also uses different approach to signal normalisation and quantification where absolute concentration cannot be provided.
- Discovery proteomics platforms lack robustness and reproducibility of targeted proteomics platforms. Targeted and discovery proteomics are distinct to the extent that a team of scientists utilising discovery proteomics platforms are generally not able to develop a targeted proteomics biomarker test without specific knowledge and experience in targeted proteomics. This is due to the above mentioned and other differences at every stage of the process, from initial concepts, sample preparation, data acquisition and processing to final test implementation in a clinical setting.
- the methods of the invention are performed using a proteolytic reference peptide and may be configured to use any suitable internal standard peptide on the same targeted proteomics platform.
- the methods of the invention may suitably be used with heavy isotopelabelled internal standards for accurate measurements. Examples of internal standards as heavy-isotope labelled proteolytic peptides are shown in Table 1 with respect to the proteolytic peptides described therein.
- the internal standard may be added to the sample before a proteolytic digestion of the proteins in the sample has occurred in step (i) of the methods of the invention. Alternatively, internal standard may be added to the sample after a proteolytic digestion of the proteins in the sample has occurred in step (i) of the methods of the invention.
- the mass spectrometer may be pre-configured using said internal standard. Suitable, heavy-isotope labels are 13 C, 15 N; and/or 2 H.
- the method of the invention may be used to assess the efficacy of a treatment regime for Parkinson’s Disease.
- the treatment regime may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- the test measures the concentration of 118 peptides, arising from 50 CSF proteins as detailed in Table 1.
- Parkinson’s disease Several proteins described herein were not previously associated with Parkinson’s disease and were not reported as biomarkers of drug treatment efficacy in Parkinson’s disease (PD).
- This protein set covers all biochemical aspects of Parkinson’s disease pathology in a single assay which include: Inflammation; Oxidative stress; Autophagy/ Lysosomal; Ubiquitin Proteasome System (UPS); Mitochondrial; Axonal/neuronal degeneration; Synaptic degeneration; Lipoprotein metabolism; Enhanced release of exosomes; Endothelial dysfunction; Amyloid Processing and other proteins relevant to PD.
- the test also includes haemoglobin as a control to monitor for CSF contamination with blood.
- the methods of the present invention may comprise steps performed by a computer and involve equipment controlled by the computer.
- the step of assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide may be performed by equipment controlled by the computer.
- the invention also provides a computer-implemented method for assessing the efficacy of a treatment for a neurodegenerative disease in a subject, which comprises receiving in a computer sample data representing the level of at least one proteolytic peptide in sample obtained from a subject and executing software on the computer to compare the level of the at least at least one proteolytic peptide in the sample to a baseline control, wherein the difference between the level of the at least one proteolytic peptide and the baseline control is indicative of the efficacy of a treatment for a neurodegenerative disease, and to output efficacy data representing the efficacy of a treatment for a neurodegenerative disease on the basis of the comparison.
- the invention also provides a computer program comprising instructions which, when executed by a computer, cause the computer to carry out a computer implemented method of the invention.
- the step of comparing the level of the at least at least one proteolytic peptide in the sample with a baseline control may be carried out on a different computer from a computer that initially receives data representing the at least at least one proteolytic peptide in the sample.
- the invention also provides a computer apparatus for assessing the efficacy of a treatment for a neurodegenerative disease, which comprises a first device incorporating a computer, a second computer and a communication channel between the first device and second computer for the transmission of data therebetween; wherein the first device is arranged to receive sample data representing level of the at least one proteolytic peptide in a sample obtained from the subject and to transmit the sample data to the second computer via the communication channel, and the second computer is arranged to execute software to compare levels of the at least at least one proteolytic peptide in the sample to a baseline control to determine the efficacy of a treatment for a neurodegenerative disease, wherein the difference between the level of the at least one proteolytic peptide and the baseline control is indicative of the efficacy of a treatment for a neurodegenerative disease, and to output efficacy data representing the efficacy of a treatment for a neurodegenerative disease on the basis of the comparison.
- the treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- the neurodegenerative disease is Parkinson’s disease.
- the second computer may be arranged to transmit the efficacy data to the first device via the communication channel, or to a third computer.
- the first device may incorporate mass spectrometry equipment or devices for measuring the level of at least one proteolytic peptide in a sample.
- test is built on the only type of mass spectrometry platform which can be accredited to existing regulatory standards and is suitable for ongoing clinical testing. Uniquely, the test measures 118 peptides at the same time in the most robust way possible as every peptide measured has a dedicated calibration line and an internal standard to provide absolute concentration and to correct for analytical signal variability. CSF sample preparation protocol has also been experimentally optimised to detect this specific set of proteins.
- test allows rapid iteration of the protein set where newly discovered molecules can be included. This also allows for this assay to be tailored to a specific therapeutic, patient population or a neurodegenerative disease (sub)type.
- the present invention provides the first comprehensive targeted proteomics biomarker test to assess treatment efficacy of new therapies in development for neurodegenerative diseases, such as Parkinson’s disease, globally.
- This test system provided by the present invention can be commercialised in a standardised “assay kit” format which will provide end-to-end solution for customers to set up in their own laboratories in addition to sending samples to a centralised testing facility.
- the methods of the present invention may be used as a biofluid test to assess treatment efficacy of novel therapies in development or existing/repurposed treatments for the treatment of a neurodegenerative disease, for example Parkinson’s Disease.
- Such uses include therapies in clinical, pre-clinical development and pharmacovigilance.
- the therapy or treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- Figure 6 shows concentration changes of 48 biomarkers. It indicates that the biomarker signature across 3 patient groups (placebo, drug treated mid-dose and drug-treated high dose) is different: in placebo group most biomarkers decrease over time, whereas in both drug treated groups the biomarkers mostly increase over time. Thus, using any number of biomarkers from this panel of 48 biomarkers it is possible to detect molecular level changes after drug treatment in a placebo controlled randomised clinical trial, indicating the application of the invention as a tool to assess drug treatment effects.
- the methods of the present invention may be used as a biofluid test to stratify subjects having a neurodegenerative disease, e.g. Parkinson’s disease patient populations, according to response to therapy.
- a neurodegenerative disease e.g. Parkinson’s disease patient populations
- Such methods would be a companion diagnostics or complementary diagnostics test or a tool for precision medicine used on clinical trials, pre- clinical studies or in healthcare settings after therapy approval.
- the therapy or treatment comprises the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- NNF neurotrophic factors
- NTF neurotrophic factor
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MEF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- a method for stratifying a subject having a neurodegenerative disease comprising:
- step (ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- Complement C3 Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-
- biomarker i.e. peptide
- All patients with biomarker signal increase i.e. an increase in concentration of the biomarker protein being assayed for
- all patients with biomarker signal decrease or not significantly changing biomarker signal i.e. a decrease in concentration of the biomarker protein being assayed for or no change in concentration
- the change in concentration may be with respect to a baseline control value or measured over a period of time (e.g. 20 weeks or 45 weeks).
- the drug treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- the neurodegenerative disease is Parkinson’s disease.
- the relative concentration of a peptide measured in the sample may refer to the concentration of the peptide relative to the corresponding labelled and/or unlabelled reference proteolytic peptide.
- Stratifying the subject according to the relative concentration of a peptide measured in the sample may comprise separating the subjects into two or more groups according to the relative concentration of a peptide measured in the sample.
- the relative concentration used for stratifying and/or grouping the subjects may be at any suitable time point, such as baseline, week 20 and/or week 45 after drug treatment. Any suitable threshold may be used for stratifying and/or grouping the subjects.
- the subjects may be stratified into two groups based on having a relative concentration of a peptide which is either above or below the average relative concentration of the peptide for all subjects being stratified.
- the average may be the mean, the median or the mode.
- the subjects may be stratified into two groups based on having a relative concentration of a peptide which is either above or below a threshold value.
- the threshold value may be predetermined.
- the threshold value may be any suitable value such as 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11 , 0.12, 0.13, 0.14 or 0.15.
- FIG. 7 shows concentration changes of 48 biomarkers over time in 5 patients who were diagnosed with Parkinson’s Disease and were treated with a novel Parkinson’s Disease drug in clinical development (CDNF).
- the figure shows biomarker concentration fold change from baseline at 6 and 12 months which is different within this patient group, i.e. Patients 2 and 4 respond differently (most biomarkers decreased after treatment) to patients 3 and 5 (biomarkers increase after treatment).
- Current expert consensus in the Parkinson’s Disease field is that Parkinson’s Disease may be a heterogenous disease at both clinical and molecular level and hence patients may respond differently to drug treatment.
- this specific drug (CDNF) is expected to elicit different responses in different Parkinson’s Disease patients as a result of its multimodal mechanism of action.
- the biomarker results obtained and shown in this figure indicate the invention provides a practical tool (for instance a CSF biomarker test) to identify these different patient groups, and therefore finds application in patient stratification.
- the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the consisting of E3 Ubiquitin-Protein Ligase TRIM33, Fast Kinase Domain-Containing Protein 5, Mitochondrial and Contactin-1.
- the proteolytic peptide of E3 Ubiquitin-Protein Ligase TRIM33 may be LFCETCDR (SEQ ID No. 40).
- the proteolytic peptide of Fast Kinase Domain-Containing Protein 5, Mitochondrial may be LAVQFTNR (SEQ ID No. 41).
- the proteolytic peptide of Contactin-1 may be IVESYQIR (SEQ ID No. 54).
- the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein wherein the protein is E3 Ubiquitin- Protein Ligase TRIM33 and the proteolytic peptide is LFCETCDR (SEQ ID No. 40).
- the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein wherein the protein Fast Kinase Domain-Containing Protein 5, Mitochondrial and the proteolytic peptide is LAVQFTNR (SEQ ID No. 41).
- the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein wherein the protein is Contactin- 1 and the proteolytic peptide is IVESYQIR (SEQ ID No. 54).
- the methods of the present invention may be used as biofluid test to help assess safety of novel therapies in development or existing treatments for neurodegenerative diseases, for example Parkinson’s Disease. This includes therapies in clinical or pre-clinical development.
- the therapy or treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the methods of the present invention may be used as biofluid test to compare severity and other aspects of neurodegenerative diseases, for example Parkinson’s disease, as a result of different aetiology (different genetic mutations, sporadic, early onset, different toxins, as a result of other conditions e.g. Gaucher disease etc).
- the methods of the present invention may be used as biofluid test for population studies to determine which sub-groups of the population develop milder or more severe Parkinson’s disease. This includes age, different geographic locations, diet, comorbidities etc.
- the methods of the present invention may be used as biofluid test to help elucidate the mechanism of action of new therapies in development.
- the methods of the present invention may be used as biofluid test as a reference method/benchmark for future tests for neurodegenerative diseases, for example Parkinson’s Disease, which includes cross- validation at test development stages.
- Parts of this test described herein may potentially be used in a future diagnostic test for a neurodegenerative disease, for example Parkinson’s disease. Parts of this test described herein may potentially be used to stratify Parkinson’s disease patient population according to disease stage/severity in clinical settings. Parts of this test described herein may potentially be used to as a prognostic/predictive tool to determine an individual’s risk to develop a neurodegenerative disease, for example Parkinson’ Disease, or a more serve form/stage of the disease
- a neurodegenerative disease comprising:
- step (ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- Complement C3 Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-
- a method for the treatment of a subject having a neurodegenerative disease comprising:
- step (a) (i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and (ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- MMP8 Neutrophil collagenase
- Complement C3 Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-
- the pharmaceutical composition may comprise one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- the neurodegenerative disease is Parkinson’s disease.
- Suitable pharmaceutical compositions for the treatment of Parkinson’s Disease included, but are not limited to: bromocriptine, cabergoline, lazabemide, levodopa, pergolide, pramipexole, rasagiline, ropinirole, rotigotine and selegiline.
- Suitable pharmaceutical compositions for the treatment of Alzheimer’s Disease included but are not limited to cholinesterase inhibitors (Cis) or inhibitors of NMDA receptor activity.
- cholinesterase inhibitors include but are not limited to tacrine, donepezil, rivastigmine, and galantamine.
- An example of an inhibitor of NMDA receptor activity is memantine.
- a method for the second-line treatment of a neurodegenerative disease in a subject comprising:
- (a) assessing the efficacy of a first-line treatment for a neurodegenerative disease in a subject comprising: (i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
- step (ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- Complement C3 Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-
- the first-line treatment of the neurodegenerative disease may be any suitable prescribed treatment regime.
- the first-line method treatment and the second-line treatment may be the same or different in terms of the pharmaceutical composition administered to the subject, dosage form and/or dosage regime.
- the first-line treatment and/or the second-line treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- the neurodegenerative disease is Parkinson’s disease.
- Suitable pharmaceutical compositions for the treatment of Parkinson’s Disease included, but are not limited to: bromocriptine, cabergoline, lazabemide, levodopa, pergolide, pramipexole, rasagiline, ropinirole, rotigotine and selegiline.
- Suitable pharmaceutical compositions for the treatment of Alzheimer’s Disease included but are not limited to cholinesterase inhibitors (Cis) or inhibitors of NMDA receptor activity.
- cholinesterase inhibitors include but are not limited to tacrine, donepezil, rivastigmine, and galantamine.
- An example of an inhibitor of NMDA receptor activity is memantine.
- kits may include a standardised set of consumables shipped to customer sites, alongside instructions on how to perform a test in their laboratories. Alternatively, instructions (standard operating procedure) detailing how to perform the test can be sold separately without consumables.
- a kit for assessing the efficacy of a first-line treatment for a neurodegenerative disease in a subject comprising: a plurality of sample preparation media for analysis of a sample by mass spectrometry for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase- 9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8).
- Complement C3 Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-
- the first-line treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties.
- the pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
- CDNF Cerebral Dopamine Neurotrophic Factor
- MMF Mesencephalic Astrocyte Derived Neurotrophic Factor
- GDNF Glial Cell-Derived Neurotrophic Factor
- the pharmaceutical composition may comprise CDNF.
- the neurodegenerative disease is Parkinson’s disease.
- the sample preparation media may comprise a protease.
- the protease is a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease or a metalloprotease.
- the protease may be trypsin.
- the sample preparation media may be suitable for use with a protease.
- the sample preparation media may comprise a buffer.
- the buffer may be suitable for use with a protease. Peptide digestion may take place in the sample preparation media.
- suitable buffers for proteases The skilled person is aware of suitable buffers for proteases.
- the sample preparation media may comprise peptide internal standards such as isotopically-labelled peptide internal standards.
- the present invention provides is the first comprehensive targeted proteomics biomarker panel for neurodegeneration. It covers all aspects of Parkinson’s disease pathology in a single, robust assay. Every molecule in the panel is measured in the most accurate way possible as there is a calibration line and a dedicated internal standard for each analyte. The panel provides absolute concentration of each analyte and is suitable for ongoing clinical testing. Overall, this test provides fundamentally richer and more reliable biomarker data.
- FIGURE 1 shows the results of differential protein expression for chromogranin-A in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples.
- WO - baseline W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
- FIGURE 2 shows the results of differential protein expression for amyloid-beta precursor protein in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples.
- WO - baseline W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
- FIGURE 3 shows the results of differential protein expression for amyloid-like protein 1 in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples.
- WO - baseline W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
- FIGURE 4 shows the results of differential protein expression for transforming growth factor-beta-induced protein IG-H3 in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples.
- WO - baseline W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
- FIGURE 5 shows the results of differential protein expression for prosaposin in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples.
- WO - baseline W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
- FIGURE 6 shows the summary of differential protein expression for all proteins in the biomarker test. Forward hatching represents fold change increase, backward hatching represents fold change decrease compared to baseline. WO - baseline, W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo. FC - fold change.
- FIGURE 7 shows the summary of differential protein expression for all proteins within a drug treated patient group, wherein the drug comprises CDNF.
- the drug comprises CDNF.
- Different biomarker trajectories demonstrate that different patients respond to treatment differently and this biomarker test may be used for patient stratification.
- Forward hatching represents fold change increase
- backward hatching represents fold change decrease compared to baseline.
- WO - baseline W20 - patients after 20 weeks of treatment with drug/placebo
- W45 - patients after 45 weeks of treatment with drug/placebo FC - fold change, MO - months.
- FIGURE 8 shows the results of differential protein expression for E3 UBIQUITIN- PROTEIN LIGASE TRIM33 in Parkinson’s Disease patients treated with a drug (CDNF).
- CDNF drug
- FIGURE 9 shows the results of differential protein expression for FAST KINASE DOMAIN-CONTAINING PROTEIN 5, MITOCHONDRIAL in Parkinson’s Disease patients treated with a drug (CDNF).
- CDNF drug
- FIGURE 10 shows the results of differential protein expression for CONTACTIN-1 in Parkinson’s Disease patients treated with a drug (CDNF).
- CDNF drug
- Protein biomarkers indicated in Figures 6 and 7 correspond to the 48 of the 50 proteins of Table 1 ; the two proteins included in Table 1 but omitted from Figures 6 and 7 are Protein MTSS 1 (Metastasis suppressor YGL-1) and Lymphocyte cytosolic protein 2.
- the method may comprise detecting an increase and/or a decrease of any one or more proteolytic peptide wherein Figure 6 and/or Figure 7 indicates an increase and/or a decrease for the corresponding biomarker.
- the increase and/or decrease may be detected in a sample obtained at any time point where an increase and/or decrease is indicated in Figure 6 (for example week 20 or week 45) and/or Figure 7 (for example, month 6 or month 12).
- the biomarker may be a biomarker that decreases in placebo at week 20 and/or week 45.
- the biomarker may be a biomarker that increases in one or more drug-treated group at week 20 and/or week 45.
- the biomarker may be a biomarker that decreases in placebo at week 20 and/or week 45 and increases in one or more drug-treated group at week 20 and/or week 45.
- the biomarker may be biomarker 23 (Neurofilament light polypeptide, (NFL)) which decreases in placebo at week 20 and increases in both drug- treated groups at week 20.
- the biomarker may be biomarker 33 (Flotillin-2, (FLOT2)) which decreases in placebo at week 20 and increases in both drug-treated groups at week 20.
- the biomarker may be biomarker 3 (Protein S100-A8 (S100A8)) which decreases in placebo at week 20 and increases in the mid-dose drug-treated group at week 20.
- the biomarker may be biomarker 41 (Peptidyl-prolyl cis-trans isomerase FKBP3 (FKBP3)) which decreases in placebo at week 20 and week 45 and increases in the mid-dose drug-treated group at week 20 and increases in the high-dose drug-treated group at week 20 and week 45.
- the increase and/or decrease may be a fold change relative to placebo for any biomarker in Figure 6.
- the biomarker may be any biomarker where Figure 7 indicates a difference between any two patients at any time point, for example at 6 months and/or at 12 months.
- the biomarker may be biomarker 48 (Neural proliferation differentiation and control protein 1 (NPDC1)) which increases in patient 3 months at 6 months and at 12 months and decreases in patients 2 and 4 at 3 months and 6 months.
- Biomarker 48 (NPDC1) is therefore an example of a biomarker which may be used to stratify patients by treatment response according to the relative concentration of a peptide measured in the sample.
- the biomarker may be any 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47 or 48 of the following proteins:
- MMP8 Neutrophil collagenase
- Apoptosis-inducing factor 1 mitochondrial
- Amyloid-like protein 1 Amyloid-like protein 1
- PDIA1 Protein disulfide-isomerase A1
- Vacuolar protein sorting-associated protein 16 homolog hVPS16
- Peptidyl-prolyl cis-trans isomerase PPIase
- HEL-S-39 Lactadherin
- Neural proliferation differentiation and control protein 1 and Ganglioside GM2 activator Neural proliferation differentiation and control protein 1 and Ganglioside GM2 activator.
- the at least one protein used in the method or kit of the invention may be any 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47 or 48 of the 48 proteins listed above.
- the at least one protein may be all 48 of the proteins listed above.
- the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of all 48 of the proteins listed above.
- Example 1 Proteomic analysis of CSF samples from Parkinson’s Disease (PD) patients undergoing treatment in clinical trial
- CDNF Cerebral Dopamine Neurotrophic Factor
- aCSF artificial cerebrospinal fluid without glucose
- Recombinant human CDNF was GMP manufactured (Biovian Ltd., Finland), formulated at 1.0 mg/ml in artificial cerebrospinal fluid without glucose (aCSF), pH 7.2, and stored below -60°C until preparation for infusion.
- Release analytics of the GMP manufactured drug product included a biological activity assay.
- aCSF (without glucose) contains 148 mM NaCI, 3 mM KCI, 1.4 mM CaCh, 0.8 mM MgCh, 0.8 mM Na2HPO4, 0.2 mM NaH2PO4 and water.
- CDNF 1.0 mg/ml diluted to administer 0.12 mg, 0.4 mg (“mid dose”), or 1.2 mg (“high dose”)
- aCSF placebo
- CSF samples were collected from Parkinson’s Disease patients by lumbar puncture in a clinical trial at baseline, 20 weeks and 45 weeks after treatment with placebo or a PD drug in development (CDNF, as described above).
- the tryptic peptides were then quantified on a liquid chromatography - tandem mass spectrometry system (LC-MS/MS), operated in timed multiple reaction monitoring mode (MRM).
- MRM timed multiple reaction monitoring mode
- a Thermo Scientific TSQ Altis triple quadrupole mass spectrometer was used for quantification.
- At least 2 unique tryptic peptides were quantified for each protein biomarker, using corresponding internal standards as shown in Table 1 and peptide calibration lines in assay buffer and CSF. A minimum of 2 transitions were used for the confident identification of each peptide as detailed in Table 2 and Table 3.
- a linear regression model was fitted through the assay buffer calibration line dataset to obtain absolute peptide concentration.
- the calibration line was plotted on a scatter plot with logarithmic axes (log-log) and 1/x 2 weighting was applied.
- the lower limits of quantification, intra-day and inter-day coefficient of variation (%CV) were also established for each peptide at multiple concentrations.
- Absolute peptide concentration was then compared across the sample set. Week 45 and Week 20 results were normalised to baseline and results expressed as fold change from baseline. 1.5-fold peptide concentration increase or 0.67- fold concentration decrease from baseline in drug treated groups whilst having no or lesser corresponding peptide alteration in the placebo group were considered to indicate drug treatment efficacy.
- biomarker i.e. peptide
- Table 1 shows 50 proteins differentially expressed in Parkinson’s Disease patients and corresponding 118 proteolytic peptide sequences with corresponding heavy isotope-labelled peptide internal standard sequences.
- Table 2 shows experimentally optimised targeted LC-MS/MS conditions to monitor native peptides listed in Table 1.
- the data in Table 2 is based on ThermoScientific triple quadruple LC-MS/MS platform TSQ Altis but is equally transferable to platforms manufactured by other companies.
- Table 2 the following abbreviations are used: RF - Radio Frequency.
- Table 3 shows experimentally optimised targeted LC-MS/MS conditions to monitor heavy isotope-labelled peptide internal standards listed i
- Table 1 This is based on ThermoScientific triple quadruple LC-MS/MS platform TSQ Altis.
- Table 2 the following abbreviations are used: RF Radio Frequency.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to a method for assessing the efficacy of a treatment for a neurodegenerative disease in a subject wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide. The invention also relates to a method for stratifying a subject having a neurodegenerative disease, a method for the diagnosis of a neurodegenerative disease, methods for the treatment of a subject having a neurodegenerative disease and a kit for assessing the efficacy of a first-line treatment for a neurodegenerative disease in a subject.
Description
METHOD FOR ASSESSING EFFICACY OF TREATMENT PROTOCOLS FOR NEURODEGENERATIVE DISEASES
The present invention relates to a method for assessing the efficacy of protocols for the treatment of neurodegenerative diseases using a multiplexed targeted proteomics-based assay.
Neurodegenerative diseases are a heterogeneous group of conditions that are characterised by the progressive degeneration of the function and structure of the peripheral nervous system or the central nervous system (CNS). The effective treatment of such diseases is increasingly important since the prevalence of the conditions is increasing in many countries. One route to study the course of treatment for such diseases is to look at biomarkers that can be obtained readily in biological samples from patients (Heywood et al., Molecular Neurodegeneration, 10, 64 (2015)).
Currently ELISA, SIMOA and other immunoassays are often used to measure a limited number of protein biomarkers in neurodegenerative diseases. Discovery proteomics may be used to measure multiple proteins at the same time although all of these technology platforms have significant limitations.
There are two main technical problems to be overcome. Firstly, the lack of comprehensive biomarker panels which would measure multiple neurodegenerative disease-relevant biomarkers. Secondly, the creation of a technology platform that would measure these multiple biomarkers in an accurate and reproducible way in a single test. Existing analytical technology platforms lack accuracy, reproducibility and/or multiplexing capacity.
Speed of deployment is another problem. It could take 6 to 9 months to raise new antibodies in addition to the time required to build an immunoassay once the antibody is available. Targeted proteomics assays can be built in 3-4 months which is an acceptable lead time for most clinical trials.
The previous work by Heywood et al. (2015) showed the utility of targeted proteomics in Parkinson’s disease in the identification of biomarkers for the disease. However, the paper does not describe the concept of identifying biomarkers for assessing the efficacy of any given treatment protocol for Parkinson’s disease.
The present invention provides a method for assessing the efficacy of a treatment protocol for a neurodegenerative disease using a multiplexed targeted proteomics assay. Suitably, the biomarkers are obtained from cerebrospinal fluid (CSF). The test provided by the invention can therefore monitor the treatment efficacy of new therapies currently in development for neurodegenerative diseases, such as Parkinson’s disease.
According to a first aspect of the invention there is provided a method for assessing the efficacy of a treatment for a neurodegenerative disease in a subject, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in T able 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta-induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide.
The treatment for the neurodegenerative disease may comprise the administration of a pharmaceutical composition comprising a pharmaceutically active substance. The administration of the pharmaceutical composition may be part of a prescribed course of treatment or a clinical trial. The pharmaceutical composition may be administered once a
day, twice a day, once a week, once a month, or at other frequencies according to the course of treatment prescribed or the clinical trial protocol. The clinical trial may be for one month, two months, 6-months or 12 months.
The pharmaceutical composition may comprise one or more neurotrophic factors (NTF) and/or one or more proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. The CDNF may comprise recombinant human CDNF. The CDNF may be administered using a neurosurgically implanted drug delivery system. The CDNF may be administered by intermittent bilateral intraputamenal infusions. The pharmaceutical composition may be administered, for example, once a month.
The efficacy of a treatment may be a measure of the effectiveness of any generally suitable method treatment for the neurodegenerative disease. The efficacy may be expressed in terms of the presence or absence of one or more clinical symptoms or one or more sideeffects of the pharmaceutical composition used to treat the subject. The efficacy of a treatment may also therefore be correlated with a change in the concentration of a protein biomarker in a sample comprising a protein as shown in Table 1. The change in the concentration of a relevant biomarker as defined herein may be an increase in concentration of a biomarker or a decrease in concentration of a biomarker compared to a baseline or control value for such a biomarker.
Absolute peptide concentration may be compared across a set of proteins in a sample. The samples may be collected at different time intervals from the start of treatment regime (i.e. time at Week 0 (“Week zero”). Subsequent samples may be collected from patients at approximately Week 20 and/or Week 45. The results for the samples obtained at different time points can then be normalised to a baseline and the results can be expressed as relative change from the baseline. For example, a 1.5-fold peptide concentration increase or 0.67-fold concentration decrease from baseline in drug treated groups whilst having no or lesser corresponding peptide alteration in the placebo group may be considered to indicate drug treatment efficacy for a pharmaceutical composition comprising a drug under assessment according to a method of the invention.
Subsequent samples may be collected from patients at approximately Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28 or 30 and/or Week 35, 40, 45, 50, 55 or 60.
Subsequent samples may be collected from patients at approximately month 1 , 2, 3, 4, 5 or 6 and/or month 7, 8, 9, 10, 11 or 12. Subsequent samples may be collected from patients at approximately six-month intervals. Subsequent samples may be collected from patients at approximately month 6 and/or month 12.
An at least 1.5-fold peptide concentration increase and/or an at least 0.67-fold concentration decrease from baseline in drug treated groups whilst having no or lesser corresponding peptide alteration in the placebo group may be considered to indicate drug treatment efficacy for a pharmaceutical composition comprising a drug under assessment according to a method of the invention.
An at least 1.1 , at least 1.2, at least 1.3, at least 1.4, at least 1.5, at least 1.6, at least 1.7, at least 1 .8, at least 1.9 or at least 2.0-fold peptide concentration increase and/or an at least 0.9, at least 0.8, at least 0.7, at least 0.6, at least 0.67, at least 0.5, at least 0.4, at least 0.3, at least 0.2 or at least 0.1 -fold concentration decrease from baseline in drug treated groups whilst having no or lesser corresponding peptide alteration in the placebo group may be considered to indicate drug treatment efficacy for a pharmaceutical composition comprising a drug under assessment according to a method of the invention.
The neurodegenerative disease may be selected from the group consisting of Parkinson’s Disease, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Batten disease or a transmissible spongiform encephalopathy (e.g. scrapie, bovine spongiform encephalopathy (BSE) or Creutzfeldt-Jakob disease (CJD), (including iatrogenic, variant, familial or sporadic forms of CJD), or a lysosomal neurodegenerative disorder (e.g. Gaucher’s disease). The neurodegenerative disease may be Parkinson’s Disease.
The first aspect of the invention may comprise a method for assessing the efficacy of a treatment for Parkinson’s disease in a subject, wherein the treatment comprises the administration of a pharmaceutical composition comprising CDNF.
As described herein, the methods of the present invention may be applicable to a broad range of other neurodegenerative conditions, such as Alzheimer’s disease, and other disease that have a neurodegenerative component, for instance rare diseases/inborn errors
of metabolism/lysosomal storage disorders etc. The test according to a method of the invention may also applicable to inflammatory conditions, for instance Cystatin C in kidney diseases.
The sample may be cerebrospinal fluid (CSF), blood (serum, whole blood (venous blood or peripheral blood), plasma, urine, tear, saliva, interstitial fluid, lymph fluid or tissue samples. The sample may be cerebrospinal fluid (CSF). The sample may be collected by any suitable means including collection of CSF by lumbar puncture, venous blood collection by direct removal from a vein or potentially via a finger prick blood collection device or a bloodspot card or plasma spot card.
The same proteins may also be measured using a different technology platform. ELISA, SIMOA, Clink, Western Blot, or other immunoassay platforms may be used to the measure the same protein set. Aptamers (oligonucleotide or peptide molecules that bind to a specific target molecule) can be used instead of antibodies in similar assays.
Different sample types may be used for this test. Currently, the test is validated on neat CSF samples but different biofluid samples, such as serum, plasma with its different sample additives (anticoagulants) may be suitable. This includes K2 and K3 EDTA plasma tubes, heparin, potassium oxalate/sodium fluoride treated plasma tubes and others.
The protease may be a serine protease (e.g. trypsin, chymotrypsin, thrombin, elastase, or subtilisin), a cysteine protease (e.g. papain, caspase-1 , adenain, pyroglutamly-peptidase I, sortase A, hepatitis C virus peptidase 2, sindbis virus-type nsP2 peptidase, dipeptidyl- peptidase VI, DeSI-1 peptidase, TEV protease, amidophosphoribozyltransferase precursor, gamma-glutamyl hydrolase, hedgehog protein, dmpA aminopeptidease), a threonine protease (e.g. ornithine acetyltransferase), an aspartic protease (e.g. pepsin, cathepsin D, cathepsin E, napsin-A, nepenthesin, presenilin, renin (chymosin)), a glutamic protease (e.g. scytalidoglutamic peptidase (eqolisin), aspergilloglutamic peptidase), a metalloprotease (e.g. an ADAM or a matrix metalloproteinase), or an asparagine peptide lyase. The protease may be trypsin.
A proteolytic peptide is therefore a peptide sequence from a protein which has been produced by the action of a protease cleaving a peptide bond between amino acids in the protein sequence. Such proteolytic peptides are therefore oligopeptides being formed of a number of amino acids. The proteolytic peptide may be from 5 to 30 amino acid residues in length, suitably 6 to 20 amino acids in length, 7 to 25 amino acids in length, or any of 5,
6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acids in length.
A proteolytic peptide prepared by the action of the protease trypsin on a protein may be referred to as a tryptic peptide and so on.
The proteolytic peptide may suitably have a sequence as set out in Table 1.
The method of the invention may comprise assaying for the presence of up to all 50 proteins in Table 1 with respect to a proteolytic peptide thereof. In some embodiments, the method of the invention may comprise assaying for the presence of a proteolytic peptide of at least 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45 or 50 proteins as shown in Table 1.
The methods of the invention therefore comprise the assaying for up to 118 proteolytic peptides of the 50 proteins shown in Table 1. In some embodiments, the method of the invention may comprise assaying for at least 5 to 10, 5 to 15, 5 to 20, 5 to 25, 5 to 30, 5 to 35, 5 to 40, 5 to 45 or 5 to 50 proteolytic peptides of Table 1. Preferably the number of proteolytic peptides assayed for is at least 5, at least 15, at least 20 or at least 25 proteolytic peptides as shown in Table 1. The number of proteolytic peptides assayed for may be 48 proteolytic peptides as shown in Table 1. When 48 proteolytic peptides shown in Table 1 are assayed for, the proteolytic peptides may be one proteolytic peptide of each protein of Table 1 except for Protein MTSS 1 (Metastasis suppressor YGL-1) and Lymphocyte cytosolic protein 2.
When more than one protein and/or proteolytic peptide is assayed for, the method can be said to comprise assaying the proteolytic digest of proteins of step (i) for the presence of a panel of proteolytic peptides of at least two proteins selected from the group of proteins as shown in Table 1. Preferably, the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a panel of proteolytic peptides of at least 48 proteins, wherein the 48 proteins are:
Matrix metalloproteinase-9 (MMP9) Chitinase-3-like protein 1 (CHI3L1) Protein S100-A8 (S100A8) Protein S100-A9 (S100A9) Neutrophil collagenase (MMP8) Complement C3 (C3)
Galectin-3-binding protein (LGALS3BP)
Catalase (CAT)
Extracellular superoxide dismutase (SOD3)
Prosaposin (PSAP)
Beta-hexosaminidase subunit beta (HEXB)
Cathepsin D (CTSD)
Beclin-1 (BECN1)
Lysosome-associated membrane glycoprotein 1 (LAMP1)
Autophagy protein 13 (ATG13)
E3 ubiquitin-protein ligase RNF26 (RNF26)
E3 ubiquitin-protein ligase TRIM33 (TRIM33)
FAST kinase domain-containing protein 5, mitochondrial (FASTKD5)
Apoptosis-inducing factor 1, mitochondrial (AIFM1)
Transmembrane protein 126A (TMEM126A)
Neurofilament light polypeptide (NFL)
Chromogranin-A (CHGA)
Contactin-1 (CNTN1)
Neurexin-1-beta (NRXN1)
Synaptotagmin-3 (SYT3)
Apolipoprotein E (APOE)
Apolipoprotein D (APOD)
Clusterin (CLU)
Flotillin-2 (FLOT2)
Cadherin-2 (CDH2)
Neural cell adhesion molecule 2 (NCAM2)
Amyloid-beta precursor protein (APP)
Amyloid-like protein 1 (APLP1)
Peptidyl-prolyl cis-trans isomerase FKBP3 (FKBP3)
Peptidyl-prolyl cis-trans isomerase FKBP4 (FKBP4)
Kallikrein-6 (KLK6)
Neutrophil gelatinase-associated lipocalin (LCN2)
Protein disulfide-isomerase A1 (PDIA1)
Limbic system-associated membrane protein (Fragment) (LSAMP)
Ceruloplasmin (CP)
Serotransferrin (TF)
Vacuolar protein sorting-associated protein 16 homolog VPS16)
Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39)
Lactadherin (MFGE8)
72 kDa type IV collagenase (MMP2)
Transforming growth factor-beta-induced protein ig-h3 (TGFBI)
Neural proliferation differentiation and control protein 1 (NPDC1) and Ganglioside GM2 activator (GM2A).
Table 1 shows 50 proteins differentially expressed in Parkinson’s Disease patients following drug treatment and corresponding 118 proteolytic peptide sequences with corresponding heavy isotope-labelled peptide internal standard sequences. The methods of the invention may comprise Table 1 also shows haemoglobin subunit beta as an optional suitable analytical control protein with corresponding proteolytic peptide sequence and corresponding heavy isotope-labelled peptide internal standard sequence.
An internal standard sequence may not be required in order to analyse the expression of any given protein according to a method of the invention. A single protein internal standard can be used for the entire biomarker test, e.g. yeast enolase without any heavy isotopelabelled internal standards. Other heavy isotope-labelled internal standards having a similar retention time can be used for quantification of peptides which do not have their own internal standards. There are examples of targeted proteomics methods which use no internal standards at all, for example the University College Dublin test for prostate cancer.
In one embodiment, the method of the invention may suitably comprise assaying for the six proteolytic peptides in the following group of proteins and corresponding proteolytic peptides:
The at least one protein may be selected from the group consisting of Chromogranin-A, Amyloid-beta Precursor Protein, Amyloid-like Protein 1 , Transforming Growth Factor-Beta- Induced Protein IG-H3, Prosaposin and Apolipoprotein E. The at least one protein may be selected from the group consisting of Chromogranin-A, Amyloid-beta Precursor Protein, Amyloid-like Protein 1 , Transforming Growth Factor-Beta-Induced Protein IG-H3 and Prosaposin.
The proteolytic peptide of at least one protein may be selected from the group consisting of:
SGELEQEEER (SEQ ID No. 52)
QQLVETHMAR (SEQ ID No. 78)
QMYPELQIAR (SEQ ID No. 85)
GDELADSALEIFK (SEQ ID No. 114)
QEILAALEK (SEQ ID No. 23) and
AATVGSLAGQPLQER (SEQ ID No. 64).
The proteolytic peptide of at least one protein may be selected from the group consisting of:
SGELEQEEER (SEQ ID No. 52)
QQLVETHMAR (SEQ ID No. 78)
QMYPELQIAR (SEQ ID No. 85)
GDELADSALEIFK (SEQ ID No. 114) and QEILAALEK (SEQ ID No. 23).
In one embodiment, the at least one protein is Chromogranin-A and the proteolytic peptide of the at least one protein is SGELEQEEER (SEQ ID No. 52).
In one embodiment, the at least one protein is Amyloid-beta Precursor Protein and the proteolytic peptide of the at least one protein is QQLVETHMAR (SEQ ID No. 78).
In one embodiment, the at least one protein is Amyloid-like Protein 1 and the proteolytic peptide of the at least one protein is QMYPELQIAR (SEQ ID No. 85). The internal standard may be QMYPELQIAR(U-13C6,15N4)VEQAT (SEQ ID No. 162).
In one embodiment, the at least one protein is Transforming Growth Factor- Beta- Induced Protein IG-H3 and the proteolytic peptide of the at least one protein is GDELADSALEIFK (SEQ ID No. 114).
In one embodiment, the at least one protein is Prosaposin and the proteolytic peptide of the at least one protein is QEILAALEK (SEQ ID No. 23). The internal standard may be QEILAALEK(U-13C6,15N2)GCSFL (SEQ ID No. 132).
In one embodiment, the at least one protein is Apolipoprotein E and the proteolytic peptide of the at least one protein is AATVGSLAGQPLQER (SEQ ID No. 64). The internal standard may be AATVGSAGQPLQER(U-13C6,15N4)AQAWG (SEQ ID No. 151).
The methods of the present invention use mass spectrometry to identify the concentrations of the peptides, for example proteolytic peptides having the sequences as set out in Table 1 . In a mass spectrometry (MS) system for the analysis of proteolytic peptides in a sample, the proteolytic peptides are injected into the MS system where the proteolytic peptides are first detected as intact peptides and then subsequently fragmented into smaller pieces which may be termed peptide fragments. The methods of the present invention provide for the detection of up to 118 proteolytic peptides of the up to 50 proteins as shown in Table 1. The concentrations of the peptides may be used to assess the efficacy of a treatment for a neurodegenerative disease and/or to stratify a subject having a neurodegenerative disease, with reference to a calibration curve of the concentrations for known reference proteolytic peptides.
The concentrations of the proteolytic peptides assayed for in the samples are therefore linked with assessing the efficacy of a treatment for a neurodegenerative disease and/or stratifying a subject having a neurodegenerative disease. Generally, a difference in proteolytic peptide concentration from a control (either increased or decreased), indicates efficacy of a treatment for a neurodegenerative disease and/or stratifying a subject having a neurodegenerative disease.
The control may be a baseline control. The control may be a placebo group. The concentrations of the proteolytic peptides may be normalised to the control. Concentrations may be expressed as fold changes relative to the control, such as fold changes from baseline.
The methods of the invention may further account for whether the proteolytic peptides are shown herein to be up-regulated or downregulated. Biomarker levels across different patients groups, for instance in a clinical trial, may be different; i.e. increased or decreased relative to another group (such as a control or a placebo). A combination of biomarkers may
be used to separate patient groups based on biomarker concentration and using a principal component analysis (PCA) or fold change differences. Fold change differences may be used to separate patient groups using a threshold or cut-off point, for example as illustrated Figures 6 & 7.
Reference peptides may be used to pre-configure the mass spectrometer prior to use in a method of the invention to detect and quantitate the concentration of peptides of Table 1 in a sample. The reference peptides also allow for the construction of calibration lines with each batch of samples tested in order to ensure robust results. Heavy isotope-labelled peptides may be used as internal standards to control analytical variability in each sample and also provide for calibration lines.
According to the present invention a mass spectrometry platform is used to measure the concentration of the analytes. Whilst triple quadrupole mass spectrometry platforms, operated in MRM mode, are preferred for this test, there could be other mass spectrometry platforms or other data acquisition modes used to design around this test. One example is high resolution mass spectrometry platforms (e.g. Sciex 6600, Thermo Orbitrap or Waters QTOF-type instruments) where “pseudo” MRM or PRM modes could be used for measurements. Triple quadrupole instruments are more robust and provide more reproducible data and thus other platforms may not reach the same performance in all aspects of the test.
There is also a variety of chromatography systems which can be coupled to a mass spectrometry platform. The test is designed to use “standard flow” (ml/min) liquid chromatography systems but lower flow systems may be used - in a range of pl/min or nl/min.
Peptide ionisation interface/method prior to mass spectrometry analysis could also be different. The test is designed to use electrospray ionisation (ESI), however the peptides can be ionised using matrix-assisted laser desorption/ionization (MALDI) or desorption electrospray ionization (DESI) or atmospheric-pressure chemical ionization (APCI) or other ionisation methods.
Different internal standards on the same targeted proteomics platform can be used. The test is designed to use heavy isotope-labelled internal standards for accurate measurements, however differently labelled or unlabelled peptide or protein internal
standards could be used which may or may not meet the performance of heavy isotopelabelled standards.
The method may comprise determining the relative concentration of the proteolytic peptide measured in the sample. The relative concentration of a peptide measured in the sample may refer to the concentration of the proteolytic peptide relative to the corresponding labelled and/or unlabelled reference proteolytic peptide.
Any of the tests described herein may be multiplexed with another test measuring proteins in a biological sample, e.g. CSF proteins, with the same technology platform. Thus, the test of the present invention may be a part of a larger test. If other treatment efficacy tests emerge, the test of the present invention could be used to augment such other tests to enhance overall performance.
The proteins from which the peptide sequences are derived are set out in Table 1 described herein. The method of the present invention may be a multiplexed assay.
As set out herein, a different peptide set to that shown in Table 1 could also be measured from the same proteins as shown in Table 1 using the same targeted proteomics platform but using a different protease. The examples of the present invention described herein show one embodiment of a method of the invention, however different peptides from the same set of 50 proteins may be used. This includes peptides generated using the same protease as in this test (trypsin) or different proteases (LysC, GluC etc).
Typically, the mass spectrometry analysis of peptides according to a method of the present invention, is liquid chromatography- targeted mass spectrometry (LC-MS) using triple quadrupole instruments, operated in timed multiple reaction monitoring (MRM) mode.
The methods of the present invention therefore comprise the use of targeted proteomics. The technique comprises the quantification of specific, pre-selected proteins or proteolytic peptides from a given sample and requires a pre-existing understanding of disease biology to guide protein selection. The technique is therefore distinct from discovery proteomics which seeks to gather information about all proteins and proteolytic peptides in a sample without pre-existing knowledge/hypotheses around disease biology. Internal standards or calibration lines for every protein or peptide of interest are not and cannot be used in discovery proteomics. Discovery proteomics is also conducted using different instrument operation modes, e.g. SWATH, HDMSE etc comparted to MRM or PRM in targeted
proteomics. Data processing also uses different approach to signal normalisation and quantification where absolute concentration cannot be provided. Discovery proteomics platforms lack robustness and reproducibility of targeted proteomics platforms. Targeted and discovery proteomics are distinct to the extent that a team of scientists utilising discovery proteomics platforms are generally not able to develop a targeted proteomics biomarker test without specific knowledge and experience in targeted proteomics. This is due to the above mentioned and other differences at every stage of the process, from initial concepts, sample preparation, data acquisition and processing to final test implementation in a clinical setting.
The methods of the invention are performed using a proteolytic reference peptide and may be configured to use any suitable internal standard peptide on the same targeted proteomics platform. The methods of the invention may suitably be used with heavy isotopelabelled internal standards for accurate measurements. Examples of internal standards as heavy-isotope labelled proteolytic peptides are shown in Table 1 with respect to the proteolytic peptides described therein. The internal standard may be added to the sample before a proteolytic digestion of the proteins in the sample has occurred in step (i) of the methods of the invention. Alternatively, internal standard may be added to the sample after a proteolytic digestion of the proteins in the sample has occurred in step (i) of the methods of the invention. The mass spectrometer may be pre-configured using said internal standard. Suitable, heavy-isotope labels are 13C, 15N; and/or 2H.
In one embodiment the method of the invention may be used to assess the efficacy of a treatment regime for Parkinson’s Disease. The treatment regime may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. The pharmaceutical composition may comprise CDNF. The test measures the concentration of 118 peptides, arising from 50 CSF proteins as detailed in Table 1. Several proteins described herein were not previously associated with Parkinson’s disease and were not reported as biomarkers of drug treatment efficacy in Parkinson’s disease (PD). This protein set covers all biochemical aspects of Parkinson’s disease pathology in a single assay which include: Inflammation; Oxidative stress; Autophagy/ Lysosomal; Ubiquitin Proteasome System (UPS); Mitochondrial; Axonal/neuronal degeneration; Synaptic degeneration; Lipoprotein
metabolism; Enhanced release of exosomes; Endothelial dysfunction; Amyloid Processing and other proteins relevant to PD. The test also includes haemoglobin as a control to monitor for CSF contamination with blood.
The methods of the present invention may comprise steps performed by a computer and involve equipment controlled by the computer. The step of assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide may be performed by equipment controlled by the computer.
The invention also provides a computer-implemented method for assessing the efficacy of a treatment for a neurodegenerative disease in a subject, which comprises receiving in a computer sample data representing the level of at least one proteolytic peptide in sample obtained from a subject and executing software on the computer to compare the level of the at least at least one proteolytic peptide in the sample to a baseline control, wherein the difference between the level of the at least one proteolytic peptide and the baseline control is indicative of the efficacy of a treatment for a neurodegenerative disease, and to output efficacy data representing the efficacy of a treatment for a neurodegenerative disease on the basis of the comparison.
The invention also provides a computer program comprising instructions which, when executed by a computer, cause the computer to carry out a computer implemented method of the invention.
It will be appreciated that the step of comparing the level of the at least at least one proteolytic peptide in the sample with a baseline control may be carried out on a different computer from a computer that initially receives data representing the at least at least one proteolytic peptide in the sample.
The invention also provides a computer apparatus for assessing the efficacy of a treatment for a neurodegenerative disease, which comprises a first device incorporating a computer, a second computer and a communication channel between the first device and second computer for the transmission of data therebetween; wherein the first device is arranged to receive sample data representing level of the at least one proteolytic peptide in a sample obtained from the subject and to transmit the sample data to the second computer via the communication channel, and the second computer is arranged to execute software to compare levels of the at least at least one proteolytic peptide in the sample to a baseline control to determine the efficacy of a treatment for a neurodegenerative disease, wherein
the difference between the level of the at least one proteolytic peptide and the baseline control is indicative of the efficacy of a treatment for a neurodegenerative disease, and to output efficacy data representing the efficacy of a treatment for a neurodegenerative disease on the basis of the comparison.
The treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. The pharmaceutical composition may comprise CDNF. Optionally, the neurodegenerative disease is Parkinson’s disease.
The second computer may be arranged to transmit the efficacy data to the first device via the communication channel, or to a third computer.
In some embodiments, the first device may incorporate mass spectrometry equipment or devices for measuring the level of at least one proteolytic peptide in a sample.
The test is built on the only type of mass spectrometry platform which can be accredited to existing regulatory standards and is suitable for ongoing clinical testing. Uniquely, the test measures 118 peptides at the same time in the most robust way possible as every peptide measured has a dedicated calibration line and an internal standard to provide absolute concentration and to correct for analytical signal variability. CSF sample preparation protocol has also been experimentally optimised to detect this specific set of proteins.
The test allows rapid iteration of the protein set where newly discovered molecules can be included. This also allows for this assay to be tailored to a specific therapeutic, patient population or a neurodegenerative disease (sub)type.
The present invention provides the first comprehensive targeted proteomics biomarker test to assess treatment efficacy of new therapies in development for neurodegenerative diseases, such as Parkinson’s disease, globally.
This test system provided by the present invention can be commercialised in a standardised “assay kit” format which will provide end-to-end solution for customers to set up in their own laboratories in addition to sending samples to a centralised testing facility.
The methods of the present invention may be used as a biofluid test to assess treatment efficacy of novel therapies in development or existing/repurposed treatments for the treatment of a neurodegenerative disease, for example Parkinson’s Disease. Such uses include therapies in clinical, pre-clinical development and pharmacovigilance. The therapy or treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. The pharmaceutical composition may comprise CDNF.
Figure 6 shows concentration changes of 48 biomarkers. It indicates that the biomarker signature across 3 patient groups (placebo, drug treated mid-dose and drug-treated high dose) is different: in placebo group most biomarkers decrease over time, whereas in both drug treated groups the biomarkers mostly increase over time. Thus, using any number of biomarkers from this panel of 48 biomarkers it is possible to detect molecular level changes after drug treatment in a placebo controlled randomised clinical trial, indicating the application of the invention as a tool to assess drug treatment effects.
The methods of the present invention may be used as a biofluid test to stratify subjects having a neurodegenerative disease, e.g. Parkinson’s disease patient populations, according to response to therapy. Such methods would be a companion diagnostics or complementary diagnostics test or a tool for precision medicine used on clinical trials, pre- clinical studies or in healthcare settings after therapy approval. Optionally, the therapy or treatment comprises the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. The pharmaceutical composition may comprise CDNF.
According to second aspect of the invention, there is provided a method for stratifying a subject having a neurodegenerative disease, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta- induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide; and
(b) stratifying the subject according to the relative concentration of a peptide measured in the sample.
To stratify patient groups after drug treatment, biomarker (i.e. peptide) trajectories within a drug treated patient group may be compared. All patients with biomarker signal increase (i.e. an increase in concentration of the biomarker protein being assayed for) may be stratified into a first subgroup whereas all patients with biomarker signal decrease or not significantly changing biomarker signal (i.e. a decrease in concentration of the biomarker protein being assayed for or no change in concentration) may be classified into a second
subgroup. The change in concentration (either increase or decrease) may be with respect to a baseline control value or measured over a period of time (e.g. 20 weeks or 45 weeks).
The drug treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. Optionally, the neurodegenerative disease is Parkinson’s disease.
The relative concentration of a peptide measured in the sample may refer to the concentration of the peptide relative to the corresponding labelled and/or unlabelled reference proteolytic peptide.
Stratifying the subject according to the relative concentration of a peptide measured in the sample may comprise separating the subjects into two or more groups according to the relative concentration of a peptide measured in the sample. The relative concentration used for stratifying and/or grouping the subjects may be at any suitable time point, such as baseline, week 20 and/or week 45 after drug treatment. Any suitable threshold may be used for stratifying and/or grouping the subjects. For example, the subjects may be stratified into two groups based on having a relative concentration of a peptide which is either above or below the average relative concentration of the peptide for all subjects being stratified. The average may be the mean, the median or the mode. Alternatively, the subjects may be stratified into two groups based on having a relative concentration of a peptide which is either above or below a threshold value. The threshold value may be predetermined. The threshold value may be any suitable value such as 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11 , 0.12, 0.13, 0.14 or 0.15.
Figure 7 shows concentration changes of 48 biomarkers over time in 5 patients who were diagnosed with Parkinson’s Disease and were treated with a novel Parkinson’s Disease drug in clinical development (CDNF). The figure shows biomarker concentration fold change from baseline at 6 and 12 months which is different within this patient group, i.e. Patients 2 and 4 respond differently (most biomarkers decreased after treatment) to patients 3 and 5 (biomarkers increase after treatment). Current expert consensus in the Parkinson’s Disease field is that Parkinson’s Disease may be a heterogenous disease at both clinical and molecular level and hence patients may respond differently to drug treatment. Further, this
specific drug (CDNF) is expected to elicit different responses in different Parkinson’s Disease patients as a result of its multimodal mechanism of action. Thus, the biomarker results obtained and shown in this figure indicate the invention provides a practical tool (for instance a CSF biomarker test) to identify these different patient groups, and therefore finds application in patient stratification.
The method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the consisting of E3 Ubiquitin-Protein Ligase TRIM33, Fast Kinase Domain-Containing Protein 5, Mitochondrial and Contactin-1. The proteolytic peptide of E3 Ubiquitin-Protein Ligase TRIM33 may be LFCETCDR (SEQ ID No. 40). The proteolytic peptide of Fast Kinase Domain-Containing Protein 5, Mitochondrial may be LAVQFTNR (SEQ ID No. 41). The proteolytic peptide of Contactin-1 may be IVESYQIR (SEQ ID No. 54).
The method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein wherein the protein is E3 Ubiquitin- Protein Ligase TRIM33 and the proteolytic peptide is LFCETCDR (SEQ ID No. 40).
The method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein wherein the protein Fast Kinase Domain-Containing Protein 5, Mitochondrial and the proteolytic peptide is LAVQFTNR (SEQ ID No. 41).
The method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein wherein the protein is Contactin- 1 and the proteolytic peptide is IVESYQIR (SEQ ID No. 54).
The methods of the present invention may be used as biofluid test to help assess safety of novel therapies in development or existing treatments for neurodegenerative diseases, for example Parkinson’s Disease. This includes therapies in clinical or pre-clinical development.
The therapy or treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF),
Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF.
The methods of the present invention may be used as biofluid test to compare severity and other aspects of neurodegenerative diseases, for example Parkinson’s disease, as a result of different aetiology (different genetic mutations, sporadic, early onset, different toxins, as a result of other conditions e.g. Gaucher disease etc).
The methods of the present invention may be used as biofluid test for population studies to determine which sub-groups of the population develop milder or more severe Parkinson’s disease. This includes age, different geographic locations, diet, comorbidities etc.
The methods of the present invention may be used as biofluid test to help elucidate the mechanism of action of new therapies in development. The methods of the present invention may be used as biofluid test as a reference method/benchmark for future tests for neurodegenerative diseases, for example Parkinson’s Disease, which includes cross- validation at test development stages.
Parts of this test described herein may potentially be used in a future diagnostic test for a neurodegenerative disease, for example Parkinson’s disease. Parts of this test described herein may potentially be used to stratify Parkinson’s disease patient population according to disease stage/severity in clinical settings. Parts of this test described herein may potentially be used to as a prognostic/predictive tool to determine an individual’s risk to develop a neurodegenerative disease, for example Parkinson’ Disease, or a more serve form/stage of the disease
According to third aspect of the invention, there is provided a method for the diagnosis of a neurodegenerative disease, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3
ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta- induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide; and
(b) diagnosing the neurodegenerative disease of the subject according to the relative concentration of a peptide measured in the sample.
According to fourth aspect of the invention, there is provided a method for the treatment of a subject having a neurodegenerative disease, the method comprising:
(a) (i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and (ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein
disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta- induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide;
(b) diagnosing the neurodegenerative disease of the subject according to the relative concentration of a peptide measured in the sample; and
(c) administering a pharmaceutical composition to the subject for the treatment of the neurodegenerative disease.
The pharmaceutical composition may comprise one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. Optionally, the neurodegenerative disease is Parkinson’s disease.
Suitable pharmaceutical compositions for the treatment of Parkinson’s Disease included, but are not limited to: bromocriptine, cabergoline, lazabemide, levodopa, pergolide, pramipexole, rasagiline, ropinirole, rotigotine and selegiline.
Suitable pharmaceutical compositions for the treatment of Alzheimer’s Disease included but are not limited to cholinesterase inhibitors (Cis) or inhibitors of NMDA receptor activity. Examples of cholinesterase inhibitors (Cis) include but are not limited to tacrine, donepezil, rivastigmine, and galantamine. An example of an inhibitor of NMDA receptor activity is memantine.
According to a fifth aspect of the invention there is provided a method for the second-line treatment of a neurodegenerative disease in a subject, the method comprising:
(a) assessing the efficacy of a first-line treatment for a neurodegenerative disease in a subject, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta- induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide; and
(b) administering a pharmaceutical composition to the subject for the second-line treatment of the neurodegenerative disease.
The first-line treatment of the neurodegenerative disease may be any suitable prescribed treatment regime. The first-line method treatment and the second-line treatment may be the same or different in terms of the pharmaceutical composition administered to the subject, dosage form and/or dosage regime.
The first-line treatment and/or the second-line treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine
Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. Optionally, the neurodegenerative disease is Parkinson’s disease.
Suitable pharmaceutical compositions for the treatment of Parkinson’s Disease included, but are not limited to: bromocriptine, cabergoline, lazabemide, levodopa, pergolide, pramipexole, rasagiline, ropinirole, rotigotine and selegiline.
Suitable pharmaceutical compositions for the treatment of Alzheimer’s Disease included but are not limited to cholinesterase inhibitors (Cis) or inhibitors of NMDA receptor activity. Examples of cholinesterase inhibitors (Cis) include but are not limited to tacrine, donepezil, rivastigmine, and galantamine. An example of an inhibitor of NMDA receptor activity is memantine.
In addition to the above, the present invention can be commercialised in an assay kit format. Such kits may include a standardised set of consumables shipped to customer sites, alongside instructions on how to perform a test in their laboratories. Alternatively, instructions (standard operating procedure) detailing how to perform the test can be sold separately without consumables.
According to a sixth aspect of the invention, there is provided a kit for assessing the efficacy of a first-line treatment for a neurodegenerative disease in a subject, comprising: a plurality of sample preparation media for analysis of a sample by mass spectrometry for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase- 9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-
associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting- associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta-induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator.
The first-line treatment may comprise the administration of a pharmaceutical composition comprising one or more neurotrophic factors (NTF) and/or proteins with neurotrophic factor (NTF) properties. The pharmaceutical composition may comprise one or more NTFs selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF). The pharmaceutical composition may comprise CDNF. Optionally, the neurodegenerative disease is Parkinson’s disease.
The sample preparation media may comprise a protease. The protease is a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease or a metalloprotease. The protease may be trypsin. Alternatively, the sample preparation media may be suitable for use with a protease.
The sample preparation media may comprise a buffer. The buffer may be suitable for use with a protease. Peptide digestion may take place in the sample preparation media. The skilled person is aware of suitable buffers for proteases.
The sample preparation media may comprise peptide internal standards such as isotopically-labelled peptide internal standards.
The present invention provides is the first comprehensive targeted proteomics biomarker panel for neurodegeneration. It covers all aspects of Parkinson’s disease pathology in a single, robust assay. Every molecule in the panel is measured in the most accurate way possible as there is a calibration line and a dedicated internal standard for each analyte. The panel provides absolute concentration of each analyte and is suitable for ongoing clinical testing. Overall, this test provides fundamentally richer and more reliable biomarker data.
Preferred features of the second and subsequent aspects of the invention are as for the first aspect mutatis mutandis.
The invention will now be described by way of reference to the following Examples which are present for the purposes of illustration only and are not to be construed as being limitations on the present invention.
Reference is also made to the following drawings, which illustrate the results of Examples 1 and 2, in which:
FIGURE 1 shows the results of differential protein expression for chromogranin-A in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples. WO - baseline, W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
FIGURE 2 shows the results of differential protein expression for amyloid-beta precursor protein in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples. WO - baseline, W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
FIGURE 3 shows the results of differential protein expression for amyloid-like protein 1 in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples. WO - baseline, W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
FIGURE 4 shows the results of differential protein expression for transforming growth factor-beta-induced protein IG-H3 in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples. WO - baseline, W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
FIGURE 5 shows the results of differential protein expression for prosaposin in Parkinson’s Disease patients. Bars represent medians; error bars represent interquartile range (IQR); dots represent individual samples. WO - baseline, W20 -
patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo
FIGURE 6 shows the summary of differential protein expression for all proteins in the biomarker test. Forward hatching represents fold change increase, backward hatching represents fold change decrease compared to baseline. WO - baseline, W20 - patients after 20 weeks of treatment with drug (CDNF)/placebo, W45 - patients after 45 weeks of treatment with drug (CDNF)/placebo. FC - fold change.
FIGURE 7 shows the summary of differential protein expression for all proteins within a drug treated patient group, wherein the drug comprises CDNF. Different biomarker trajectories demonstrate that different patients respond to treatment differently and this biomarker test may be used for patient stratification. Forward hatching represents fold change increase, backward hatching represents fold change decrease compared to baseline. WO - baseline, W20 - patients after 20 weeks of treatment with drug/placebo, W45 - patients after 45 weeks of treatment with drug/placebo. FC - fold change, MO - months.
FIGURE 8 shows the results of differential protein expression for E3 UBIQUITIN- PROTEIN LIGASE TRIM33 in Parkinson’s Disease patients treated with a drug (CDNF). Different biomarker trajectories demonstrate that different patients respond to treatment differently and this biomarker test may be used for patient stratification. Dots represent individual samples. WO - baseline, W20 - patients after 20 weeks of treatment with drug, W45 - patients after 45 weeks of treatment with drug.
FIGURE 9 shows the results of differential protein expression for FAST KINASE DOMAIN-CONTAINING PROTEIN 5, MITOCHONDRIAL in Parkinson’s Disease patients treated with a drug (CDNF). Different biomarker trajectories demonstrate that different patients respond to treatment differently and this biomarker test may be used for patient stratification. Dots represent individual samples. WO - baseline, W20 - patients after 20 weeks of treatment with drug, W45 - patients after 45 weeks of treatment with drug.
FIGURE 10 shows the results of differential protein expression for CONTACTIN-1 in Parkinson’s Disease patients treated with a drug (CDNF). Different biomarker trajectories demonstrate that different patients respond to treatment differently and this biomarker test may be used for patient stratification, Dots represent individual
samples. WO - baseline, W20 - patients after 20 weeks of treatment with drug, W45 - patients after 45 weeks of treatment with drug.
Protein biomarkers indicated in Figures 6 and 7 correspond to the 48 of the 50 proteins of Table 1 ; the two proteins included in Table 1 but omitted from Figures 6 and 7 are Protein MTSS 1 (Metastasis suppressor YGL-1) and Lymphocyte cytosolic protein 2.
The method may comprise detecting an increase and/or a decrease of any one or more proteolytic peptide wherein Figure 6 and/or Figure 7 indicates an increase and/or a decrease for the corresponding biomarker. The increase and/or decrease may be detected in a sample obtained at any time point where an increase and/or decrease is indicated in Figure 6 (for example week 20 or week 45) and/or Figure 7 (for example, month 6 or month 12). With reference to Figure 6, the biomarker may be a biomarker that decreases in placebo at week 20 and/or week 45. With reference to Figure 6, the biomarker may be a biomarker that increases in one or more drug-treated group at week 20 and/or week 45. With reference to Figure 6, the biomarker may be a biomarker that decreases in placebo at week 20 and/or week 45 and increases in one or more drug-treated group at week 20 and/or week 45. For example, the biomarker may be biomarker 23 (Neurofilament light polypeptide, (NFL)) which decreases in placebo at week 20 and increases in both drug- treated groups at week 20. For example, the biomarker may be biomarker 33 (Flotillin-2, (FLOT2)) which decreases in placebo at week 20 and increases in both drug-treated groups at week 20. For example, the biomarker may be biomarker 3 (Protein S100-A8 (S100A8)) which decreases in placebo at week 20 and increases in the mid-dose drug-treated group at week 20. For example, the biomarker may be biomarker 41 (Peptidyl-prolyl cis-trans isomerase FKBP3 (FKBP3)) which decreases in placebo at week 20 and week 45 and increases in the mid-dose drug-treated group at week 20 and increases in the high-dose drug-treated group at week 20 and week 45. The increase and/or decrease may be a fold change relative to placebo for any biomarker in Figure 6. The biomarker may be any biomarker where Figure 7 indicates a difference between any two patients at any time point, for example at 6 months and/or at 12 months. For example, the biomarker may be biomarker 48 (Neural proliferation differentiation and control protein 1 (NPDC1)) which increases in patient 3 months at 6 months and at 12 months and decreases in patients 2 and 4 at 3 months and 6 months. Biomarker 48 (NPDC1) is therefore an example of a biomarker which may be used to stratify patients by treatment response according to the relative concentration of a peptide measured in the sample. The biomarker may be any 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28,
29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47 or 48 of the following proteins:
Matrix metalloproteinase-9
Chitinase-3-like protein 1
Protein S100-A8
Protein S100-A9
Neutrophil collagenase (MMP8)
Complement C3
Galectin-3-binding protein
Catalase
Extracellular superoxide dismutase
Prosaposin
Beta-hexosaminidase subunit beta
Cathepsin D
Beclin-1
Lysosome-associated membrane glycoprotein 1
Autophagy protein 13
E3 ubiquitin-protein ligase RNF26
E3 ubiquitin-protein ligase TRIM33
FAST kinase domain-containing protein 5, mitochondrial
Apoptosis-inducing factor 1 , mitochondrial
Transmembrane protein 126A
Neurofilament light polypeptide
Chromogranin-A
Contactin-1
Neurexin-1-beta
Synaptotagmin-3
Apolipoprotein E
Apolipoprotein D
Clusterin
Flotillin-2
Cadherin-2
Neural cell adhesion molecule 2
Amyloid-beta precursor protein
Amyloid-like protein 1
Peptidyl-prolyl cis-trans isomerase FKBP3
Peptidyl-prolyl cis-trans isomerase FKBP4
Kallikrein-6
Neutrophil gelatinase-associated lipocalin
Protein disulfide-isomerase A1 (PDIA1)
Limbic system-associated membrane protein (Fragment)
Ceruloplasmin
Serotransferrin
Vacuolar protein sorting-associated protein 16 homolog (hVPS16) Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39) Lactadherin
72 kDa type IV collagenase
Transforming growth factor-beta-induced protein ig-h3
Neural proliferation differentiation and control protein 1 and Ganglioside GM2 activator.
Therefore, the at least one protein used in the method or kit of the invention may be any 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47 or 48 of the 48 proteins listed above. Preferably, the at least one protein may be all 48 of the proteins listed above. Accordingly, the method may comprise assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of all 48 of the proteins listed above.
Further advantages of the invention include:
• Showing it is possible to develop a highly multiplexed biomarker assay that covers all aspects of Parkinson’s Disease molecular pathology in a single test. Table 1 details these disease processes, proteins selected and their corresponding tryptic peptides. The inventors believe this is the world’s first comprehensive targeted proteomics biomarker panel for Parkinson’s Disease /neurodegeneration.
• Showing it is possible to apply this test to stratify patient population and to assess drug treatment effects (Figures 6 & 7).
• Showing how to set up this biomarker test on a specific analytical instrument which a skilled person in the field will be able to do by referring to Tables 1 & 2 and application text. Table 2 discloses specific instruments settings to the level of detail where these can be directly copied to set up this biomarker test.
• Revealing proteins that were previously not associated with Parkinson’s Disease, and that these proteins are a part of the method to stratify patient populations in Parkinson’s Disease and to assess drug treatment effects.
• Showing that it is possible to establish this comprehensive panel of biomarkers on specific analytical instruments which provide more accurate and robust analytical measurements for every single molecule in the panel compared to other analytical technologies; and that this assay can be validated to existing regulatory standards in clinical settings.
• Overall, this biomarker test provides fundamentally richer and more reliable biomarker data compared to other technologies in the field.
Example 1 : Proteomic analysis of CSF samples from Parkinson’s Disease (PD) patients undergoing treatment in clinical trial
Study Design
PD patients were treated with either Cerebral Dopamine Neurotrophic Factor (CDNF) or a placebo comprising artificial cerebrospinal fluid without glucose (aCSF). CDNF or aCSF were administered via a neurosurgically implanted drug delivery system (with two catheter tips placed in the putamen bilaterally).
Recombinant human CDNF was GMP manufactured (Biovian Ltd., Finland), formulated at 1.0 mg/ml in artificial cerebrospinal fluid without glucose (aCSF), pH 7.2, and stored below -60°C until preparation for infusion. Release analytics of the GMP manufactured drug product included a biological activity assay. aCSF (without glucose) contains 148 mM NaCI, 3 mM KCI, 1.4 mM CaCh, 0.8 mM MgCh, 0.8 mM Na2HPO4, 0.2 mM NaH2PO4 and water.
CDNF (1.0 mg/ml diluted to administer 0.12 mg, 0.4 mg (“mid dose”), or 1.2 mg (“high dose”)) or aCSF (placebo) was administered to the PD patients via intraputamenal infusions on a monthly basis for 6 months (placebo-controlled main study), and with 0.4 mg (“mid dose”) or 1 .2 mg (“high dose”) for another 6-month period (extension study).
Sample collection
CSF samples were collected from Parkinson’s Disease patients by lumbar puncture in a clinical trial at baseline, 20 weeks and 45 weeks after treatment with placebo or a PD drug in development (CDNF, as described above).
Sample Preparation
Equal volumes of CSF were freeze-dried and isotopically-labelled peptide internal standards were added prior to protein digestion. CSF proteins were enzymatically digested into peptides using Trypsin, with prior reduction and alkylation. After digestion, samples were purified using a C18-based solid phase extraction microplate before injection into LC- MS/MS system.
LC-MS/MS Set Up
The tryptic peptides were then quantified on a liquid chromatography - tandem mass spectrometry system (LC-MS/MS), operated in timed multiple reaction monitoring mode (MRM). A Thermo Scientific TSQ Altis triple quadrupole mass spectrometer was used for quantification. At least 2 unique tryptic peptides were quantified for each protein biomarker, using corresponding internal standards as shown in Table 1 and peptide calibration lines in assay buffer and CSF. A minimum of 2 transitions were used for the confident identification of each peptide as detailed in Table 2 and Table 3. Each patient sample was injected onto a Kinetex reversed phase C18-based liquid chromatography column and peptides separated with water and acetonitrile gradient at 0.5ml/min flow rate. The samples were run blinded and in a random order. Chromatograms were analyzed using Xcalibur v4.1 software and absolute concentration was obtained from standard curves, constructed with peptides shown in Table 1. A standard curve of each peptide was analyzed at the start and the end of the run for quantitation and performance standardization.
Statistical Analysis/Results Interpretation
A linear regression model was fitted through the assay buffer calibration line dataset to obtain absolute peptide concentration. The calibration line was plotted on a scatter plot with logarithmic axes (log-log) and 1/x2 weighting was applied. The lower limits of quantification, intra-day and inter-day coefficient of variation (%CV) were also established for each peptide at multiple concentrations. Absolute peptide concentration was then compared across the sample set. Week 45 and Week 20 results were normalised to baseline and results expressed as fold change from baseline. 1.5-fold peptide concentration increase or 0.67- fold concentration decrease from baseline in drug treated groups whilst having no or lesser corresponding peptide alteration in the placebo group were considered to indicate drug treatment efficacy.
Example 2: Stratification of patients
To stratify patient groups after drug treatment with CDNF, as described above with respect to Example 1 , biomarker (i.e. peptide) trajectories within a drug treated patient group were compared. All patients with biomarker signal increase were stratified into subgroup 1
whereas all patients with biomarker signal decrease or not significantly changing biomarker signal were classified into subgroup 2.
Reference is also made in the present application to the following Table:
Table 1 shows 50 proteins differentially expressed in Parkinson’s Disease patients and corresponding 118 proteolytic peptide sequences with corresponding heavy isotope-labelled peptide internal standard sequences.
Table 2 shows experimentally optimised targeted LC-MS/MS conditions to monitor native peptides listed in Table 1. The data in Table 2 is based on ThermoScientific triple quadruple LC-MS/MS platform TSQ Altis but is equally transferable to platforms manufactured by other companies. In Table 2, the following abbreviations are used: RF - Radio Frequency.
Table 3 shows experimentally optimised targeted LC-MS/MS conditions to monitor heavy isotope-labelled peptide internal standards listed i
Table 1. This is based on ThermoScientific triple quadruple LC-MS/MS platform TSQ Altis. In Table 2, the following abbreviations are used: RF Radio Frequency.
Claims
1 . A method for assessing the efficacy of a treatment for a neurodegenerative disease in a subject, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in T able 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta-induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide.
2. A method for stratifying a subject having a neurodegenerative disease, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3,
Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta- induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide; and
(b) stratifying the subject according to the relative concentration of a peptide measured in the sample.
3. A method for the diagnosis of a neurodegenerative disease, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor
protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta- induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide; and
(b) diagnosing the neurodegenerative disease of the subject according to the relative concentration of a peptide measured in the sample.
4. A method for the treatment of a subject having a neurodegenerative disease, the method comprising:
(a) (i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and (ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta-
induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator, wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide;
(b) diagnosing the neurodegenerative disease of the subject according to the relative concentration of a peptide measured in the sample; and
(c) administering a pharmaceutical composition to the subject for the treatment of the neurodegenerative disease.
5. A method for the second-line treatment of a neurodegenerative disease in a subject, the method comprising:
(a) assessing the efficacy of a first -line treatment for a neurodegenerative disease in a subject, the method comprising:
(i) preparing a biological sample from the subject for assay by incubating the sample with a protease to form a proteolytic digest of proteins in the sample; and
(ii) assaying the proteolytic digest of proteins of step (i) for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-9, Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase-associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting-associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta- induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator,
wherein the presence of said proteolytic peptide is assayed for using mass spectrometry with reference to a corresponding labelled and/or unlabelled reference proteolytic peptide; and
(b) treating the subject with a pharmaceutical composition for the second-line treatment of the neurodegenerative disease.
6. The method of any preceding claim wherein the protease is a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease or a metalloprotease.
7. The method of any preceding claim wherein the protease is trypsin.
8. A kit for assessing the efficacy of a first-line treatment for a neurodegenerative disease in a subject, comprising: a plurality of sample preparation media for analysis of a sample by mass spectrometry for the presence of a proteolytic peptide of at least one protein selected from the group of proteins as shown in Table 1 , said group consisting of Matrix metalloproteinase-
9. Chitinase-3-like protein 1 , Protein S100-A8, Protein S100-A9, Neutrophil collagenase (MMP8). Complement C3, Galectin-3-binding protein, Catalase, Extracellular superoxide dismutase, Prosaposin, Beta-hexosaminidase subunit beta, Cathepsin D, Beclin-1 , Lysosome-associated membrane glycoprotein 1 , Autophagy protein 13, E3 ubiquitin-protein ligase RNF26, E3 ubiquitin-protein ligase TRIM33, FAST kinase domain-containing protein 5, mitochondrial, Apoptosis-inducing factor 1 mitochondrial, Transmembrane protein 126A, Neurofilament light polypeptide, Chromogranin-A, Contactin-1 , Neurexin-1-beta, Protein MTSS 1 (Metastasis suppressor YGL-1), Synaptotagmin-3, Apolipoprotein E, Apolipoprotein D, Clusterin, Flotillin-2, Cadherin-2, Neural cell adhesion molecule 2, Amyloid-beta precursor protein, Amyloid-like protein 1 , Peptidyl-prolyl cis-trans isomerase FKBP3, Peptidyl-prolyl cis-trans isomerase FKBP4, Kallikrein-6, Neutrophil gelatinase- associated lipocalin, Protein disulfide-isomerase A1 (PDIA1), Limbic system-associated membrane protein (Fragment), Ceruloplasmin, Serotransferrin, Vacuolar protein sorting- associated protein 16 homolog (hVPS16), Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39), Lymphocyte cytosolic protein 2, Lactadherin, 72 kDa type IV collagenase, Transforming growth factor-beta-induced protein ig-h3, Neural proliferation differentiation and control protein 1 , Ganglioside GM2 activator.
9. The kit according to claim 8, wherein the sample preparation media comprises a protease, optionally wherein the protease is a serine protease, a cysteine protease, a threonine protease, an aspartic protease, a glutamic protease or a metalloprotease.
10. The kit according to claim 9 wherein the protease is trypsin.
11. The method or kit of any preceding claim wherein the neurodegenerative disease is selected from the group consisting of Parkinson’s Disease, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Batten disease or a transmissible spongiform encephalopathy (e.g. scrapie, bovine spongiform encephalopathy (BSE) or Creutzfeldt-Jakob disease (CJD), (including iatrogenic, variant, familial or sporadic forms of CJD), or a lysosomal neurodegenerative disorder (e.g. Gaucher’s disease).
12. The method or kit of any preceding claim wherein the neurodegenerative disease is Parkinson’s Disease.
13. The method or kit of any preceding claim wherein the sample is selected from the group consisting of cerebrospinal fluid (CSF), blood (serum, whole blood (venous blood or peripheral blood), plasma, urine, tear, saliva, interstitial fluid, lymph fluid or tissue samples.
14. The method or kit of any preceding claim wherein the sample is cerebrospinal fluid (CSF).
15. The method or kit of any preceding claim wherein the proteolytic peptide of at least one protein is selected from the group consisting of:
VNVDEVGGEALGR (SEQ ID No. 1)
AFALWSAVTPLTFTR (SEQ ID No. 2)
QLSLPETGELDSATLK (SEQ ID No. 3)
LVMGIPTFGR (SEQ ID No. 4)
TLLSVGGWNFGSQR (SEQ ID No. 5)
FSNTDYAVGYMLR (SEQ ID No. 6)
ALNSIIDVYHK (SEQ ID No. 7)
GNFHAVYR (SEQ ID No. 8)
VIEHIMEDLDTNADK (SEQ ID No. 9)
LTWASHEK (SEQ ID No. 10)
YYAFDLIAQR (SEQ ID No. 11)
VDAVFQQEHFFHVFSGPR (SEQ ID No. 12) VLLDGVQNPR (SEQ ID No. 13) NTLIIYLDK (SEQ ID No. 14) ASHEEVEGLVEK (SEQ ID No. 15) SQLVYQSR (SEQ ID No. 16) IYTSPTWSAFVTDSSWSAR (SEQ ID No. 17) FSTVAGESGSADTVR (SEQ ID No. 18) GAGAFGYFEVTHDITK (SEQ ID No. 19) AGLAASLAGPHSIVGR (SEQ ID No. 20) AVVVHAGEDDLGR (SEQ ID No. 21) EILDAFDK (SEQ ID No. 22) QEILAALEK (SEQ ID No. 23) VEPLDFGGTQK (SEQ ID No. 24) VLDIIATINK (SEQ ID No. 25) LSPEDYTLK (SEQ ID No. 26) VSTLPAITLK (SEQ ID No. 27) WGLAWVSSQFYNK (SEQ ID No. 28) TSNNSTMQVSFVCQR (SEQ ID No. 29) ELALEEER (SEQ ID No. 30) ENTSDPSLVIAFGR (SEQ ID No. 31) TVESITDIR (SEQ ID No. 32) ALQATVGNSYK (SEQ ID No. 33) DDILPMDLGTFYR (SEQ ID No. 34) TVQVIVQAR (SEQ ID No. 35) LLGHLASHGALR (SEQ ID No. 36) QDTLPEAGR (SEQ ID No. 37) SLQLASWPNR (SEQ ID No. 38) QIDLVDNYFVK (SEQ ID No. 39) LFCETCDR (SEQ ID No. 40) LAVQFTNR (SEQ ID No. 41) ASTLQLGSPR (SEQ ID No. 42) GVIFYLR (SEQ ID No. 43) ELWFSDDPNVTK (SEQ ID No. 44) YQSALLPHK (SEQ ID No. 45) ENITIVDISR (SEQ ID No. 46) YEEEVLSR (SEQ ID No. 47) IDSLMDEISFLK (SEQ ID No. 48)
VLEAELLVLR (SEQ ID No. 49)
FTVLTESAAK (SEQ ID No. 50)
YPGPQAEGDSEGLSQGLVDR (SEQ ID No. 51)
SGELEQEEER (SEQ ID No. 52)
FIPLIPIPER (SEQ ID No. 53)
IVESYQIR (SEQ ID No. 54)
SDLYIGGVAK (SEQ ID No. 55)
ITTQITAGAR (SEQ ID No. 56)
TTVVAAAAFLDAFQK (SEQ ID No. 57)
SLTMDPHK (SEQ ID No. 58)
YLYGSDQLVVR (SEQ ID No. 59)
ILQALDLPAK (SEQ ID No. 60)
KPVEHWHQLVEVSR (SEQ ID No. 61)
GPTPTPDK (SEQ ID No. 62)
HPC(Carbamidomethyl)TLGPFIHATNALHVR (SEQ ID No. 63)
AATVGSLAGQPLQER (SEQ ID No. 64)
GEVQAMLGQSTEELR (SEQ ID No. 65)
LGPLVEQGR (SEQ ID No. 66)
IPTTFENGR (SEQ ID No. 67)
VLNQELR (SEQ ID No. 68)
VTTVASHTSDSDVPSGVTEVVVK (SEQ ID No. 69)
ASSIIDELFQDR (SEQ ID No. 70)
NVVLQTLEGHLR (SEQ ID No. 71)
EGHLRSILGTLTVEQIYQDRDQFAK (SEQ ID No. 72)
TAEAQLAYELQGAR (SEQ ID No. 73)
GPFPQELVR (SEQ ID No. 74)
DVHEGQPLLNVK (SEQ ID No. 75)
EVVSPQEFK (SEQ ID No. 76)
ALLQVTISLSK (SEQ ID No. 77)
QQLVETHMAR (SEQ ID No. 78)
GAIIGLMVGGVV (SEQ ID No. 79)
GAIIGLMVGGVVIA (SEQ ID No. 80)
LVFFAEDVGSNK (SEQ ID No. 81)
WYFDVTEGK (SEQ ID No. 82)
DDTPMTLPK (SEQ ID No. 83)
HGYENPTYR (SEQ ID No. 84)
QMYPELQIAR (SEQ ID No. 85)
AWTVEQLR (SEQ ID No. 86)
SEETLDEGPPK (SEQ ID No. 87)
ESWEMNSEEK (SEQ ID No. 88)
ALELDSNNEK (SEQ ID No. 89)
LSELIQPLPLER (SEQ ID No. 90)
YTNWIQK (SEQ ID No. 91)
MYATIYELK (SEQ ID No. 92)
VPLQQNFQDNQFQGK (SEQ ID No. 93)
MDSTANEVEAVK (SEQ ID No. 94)
ALAPEYAK (SEQ ID No. 95)
VTVNYPPTITESK (SEQ ID No. 96)
SGIIFAGHDK (SEQ ID No. 97)
MYYSAVEPTK (SEQ ID No. 98)
IYHSHIDAPK (SEQ ID No. 99)
DSAHGFLK (SEQ ID No. 100)
DGAGDVAFVK (SEQ ID No. 101)
LGDTPGVSYSDIAAR (SEQ ID No. 102)
ALLLVGDVAQAADVAIEHR (SEQ ID No. 103)
TVDNFVALATGEK (SEQ ID No. 104)
VYFDLR (SEQ ID No. 105)
FLNLTENDIQK (SEQ ID No. 106)
LPAPSIDR (SEQ ID No. 107)
GKEDFLSVSDIIDYFR (SEQ ID No. 108)
VTFLGLQHWVPELAR (SEQ ID No. 109)
LASHEYLK (SEQ ID No. 110)
AFQVWSDVTPLR (SEQ ID No. 111)
FFGLPQTGDLDQNTIETMR (SEQ ID No. 112)
LTLLAPLNSVFK (SEQ ID No. 113)
GDELADSALEIFK (SEQ ID No. 114)
LPEPATLGFSAR (SEQ ID No. 115)
NPLFDHAALSAPLPAPSSPPALP (SEQ ID No. 116)
SEFVVPDLELPSWLTTGNYR (SEQ ID No. 117) and EGTYSLPK (SEQ ID No. 118).
16. The method or kit of any preceding claim wherein the at least one protein is selected from the group consisting of Chromogranin-A, Amyloid-beta Precursor Protein, Amyloid-like
Protein 1, Transforming Growth Factor-Beta-Induced Protein IG-H3, Prosaposin and Apolipoprotein E.
17. The method or kit of any preceding claim wherein the proteolytic peptide of at least one protein is selected from the group consisting of:
SGELEQEEER (SEQ ID No. 52)
QQLVETHMAR (SEQ ID No. 78)
QMYPELQIAR (SEQ ID No. 85)
GDELADSALEIFK (SEQ ID No. 114)
QEILAALEK (SEQ ID No. 23) and
AATVGSLAGQPLQER (SEQ ID No. 64).
18. The method or kit of any one of claims 1 to 15 wherein the at least one protein is selected from the group consisting of:
Matrix metalloproteinase-9
Chitinase-3-like protein 1
Protein S100-A8
Protein S100-A9
Neutrophil collagenase (MMP8)
Complement C3
Galectin-3-binding protein
Catalase
Extracellular superoxide dismutase
Prosaposin
Beta-hexosaminidase subunit beta
Cathepsin D
Beclin-1
Lysosome-associated membrane glycoprotein 1
Autophagy protein 13
E3 ubiquitin-protein ligase RNF26
E3 ubiquitin-protein ligase TRIM33
FAST kinase domain-containing protein 5, mitochondrial
Apoptosis-inducing factor 1, mitochondrial
Transmembrane protein 126A
Neurofilament light polypeptide
Chromogranin-A
Contactin-1
Neurexin-1-beta
Synaptotagmin-3
Apolipoprotein E
Apolipoprotein D
Clusterin
Flotillin-2
Cadherin-2
Neural cell adhesion molecule 2
Amyloid-beta precursor protein
Amyloid-like protein 1
Peptidyl-prolyl cis-trans isomerase FKBP3
Peptidyl-prolyl cis-trans isomerase FKBP4 Kallikrein-6
Neutrophil gelatinase-associated lipocalin
Protein disulfide-isomerase A1 (PDIA1)
Limbic system-associated membrane protein (Fragment)
Ceruloplasmin
Serotransferrin
Vacuolar protein sorting-associated protein 16 homolog (hVPS16)
Peptidyl-prolyl cis-trans isomerase (PPIase; HEL-S-39) Lactadherin
72 kDa type IV collagenase
Transforming growth factor-beta-induced protein ig-h3
Neural proliferation differentiation and control protein 1 and Ganglioside GM2 activator.
19. The method or kit of claim 18 wherein the at least one protein is all 48 of the proteins according to claim 18.
20. The method or kit of any one of claims 1 to 15 wherein the at least one protein is selected from the consisting of E3 Ubiquitin-Protein Ligase TRIM33, Fast Kinase Domain- Containing Protein 5, Mitochondrial and Contactin-1.
21. The method or kit of claim 20 wherein the proteolytic peptide of E3 Ubiquitin-Protein Ligase TRIM33 is LFCETCDR (SEQ ID No. 40); the proteolytic peptide of Fast Kinase Domain-Containing Protein 5, Mitochondrial is LAVQFTNR (SEQ ID No. 41); and/or the proteolytic peptide of Contactin-1 is IVESYQIR (SEQ ID No. 54).
22. The method of any of claim 1 , and claims 6, 7 and 11 to 21 insofar as they depend on claim 1 , wherein the treatment comprises the administration of a pharmaceutical composition comprising one or more neurotrophic factors.
23. The method of any of claim 2, and claims 6, 7 and 11 to 21 insofar as they depend on claim 2, wherein the subject for assay has been treated with a pharmaceutical composition comprising one or more neurotrophic factors.
24. The method of any of claim 4, and claims 6, 7 and 11 to 21 insofar as they depend on claim 4, wherein the pharmaceutical composition comprises one or more neurotrophic factors.
25. The method of any of claim 5, and claims 6, 7 and 11 to 21 insofar as they depend on claim 5, wherein the first-line treatment and/or the second-line treatment comprises the administration of a pharmaceutical composition comprising one or more neurotrophic factors.
26. The kit of any of claim 8, and claims 9 to 21 insofar as they depend on claim 8, wherein the first-line treatment comprises the administration of a pharmaceutical composition comprising one or more neurotrophic factors.
27. The method or kit of any of claims 22 to 26, wherein the one or more neurotrophic factors comprise one or more neurotrophic factors selected from the group consisting of Cerebral Dopamine Neurotrophic Factor (CDNF), Mesencephalic Astrocyte Derived Neurotrophic Factor (MANF) and Glial Cell-Derived Neurotrophic Factor (GDNF).
28. The method or kit of claim 27, wherein the one or more neurotrophic factors comprise CDNF.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/074901 WO2024051937A1 (en) | 2022-09-07 | 2022-09-07 | Method for assessing efficacy of treatment protocols for neurodegenerative diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2022/074901 WO2024051937A1 (en) | 2022-09-07 | 2022-09-07 | Method for assessing efficacy of treatment protocols for neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024051937A1 true WO2024051937A1 (en) | 2024-03-14 |
Family
ID=83280474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/074901 WO2024051937A1 (en) | 2022-09-07 | 2022-09-07 | Method for assessing efficacy of treatment protocols for neurodegenerative diseases |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024051937A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005019825A2 (en) * | 2003-08-20 | 2005-03-03 | Genova Ltd. | Secreted polypeptide species and use thereof |
WO2008063369A2 (en) * | 2006-11-01 | 2008-05-29 | George Mason Intellectual Properties, Inc. | Biomarkers for neurological conditions |
WO2013151726A1 (en) * | 2012-04-05 | 2013-10-10 | Integrated Diagnostics, Inc. | Srm methods in alzheimer's disease and neurological disease assays |
WO2016069461A1 (en) * | 2014-10-27 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | A parkinson's disease diagnostic biomarker panel |
WO2018145211A1 (en) * | 2017-02-10 | 2018-08-16 | UNIVERSITé LAVAL | Erythrocyte-derived extracellular vesicles and proteins associated with such vesicles as biomarkers for parkinson's disease |
WO2018231415A1 (en) * | 2017-06-16 | 2018-12-20 | C2N Diagnostics Llc | Methods for extracting and measuring concentrations of biomolecules in complex matrices without the need for immunocapture |
-
2022
- 2022-09-07 WO PCT/EP2022/074901 patent/WO2024051937A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005019825A2 (en) * | 2003-08-20 | 2005-03-03 | Genova Ltd. | Secreted polypeptide species and use thereof |
WO2008063369A2 (en) * | 2006-11-01 | 2008-05-29 | George Mason Intellectual Properties, Inc. | Biomarkers for neurological conditions |
WO2013151726A1 (en) * | 2012-04-05 | 2013-10-10 | Integrated Diagnostics, Inc. | Srm methods in alzheimer's disease and neurological disease assays |
WO2016069461A1 (en) * | 2014-10-27 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | A parkinson's disease diagnostic biomarker panel |
WO2018145211A1 (en) * | 2017-02-10 | 2018-08-16 | UNIVERSITé LAVAL | Erythrocyte-derived extracellular vesicles and proteins associated with such vesicles as biomarkers for parkinson's disease |
WO2018231415A1 (en) * | 2017-06-16 | 2018-12-20 | C2N Diagnostics Llc | Methods for extracting and measuring concentrations of biomolecules in complex matrices without the need for immunocapture |
Non-Patent Citations (1)
Title |
---|
LORENZL STEFAN ET AL: "Matrix Metalloproteinase-9 Is Elevated in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism in Mice", NEUROMOLECULAR MEDICINE, vol. 5, no. 2, 1 January 2004 (2004-01-01), pages 119 - 132, XP055932232, Retrieved from the Internet <URL:https://link.springer.com/content/pdf/10.1385/NMM:5:2:119.pdf> DOI: 10.1385/NMM:5:2:119 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mischak et al. | Comprehensive human urine standards for comparability and standardization in clinical proteome analysis | |
EP1825274B1 (en) | Monitoring Huntington's disease | |
US11467167B2 (en) | SRM methods in Alzheimer's disease and neurological disease assays | |
US20050064516A1 (en) | Biological markers for diagnosing multiple sclerosis | |
Ambatipudi et al. | Quantitative proteomics of parotid saliva in primary Sjögren's syndrome | |
US8506957B2 (en) | Methods and compositions for monitoring progression of huntington's disease | |
Zhang et al. | Preliminary characterizations of a serum biomarker for sarcoidosis by comparative proteomic approach with tandem-mass spectrometry in ethnic Han Chinese patients | |
WO2007106762A2 (en) | Alzheimer's disease biomarkers and methods of use | |
WO2019149816A1 (en) | Method for the diagnosis of hereditary angioedema | |
KR101391506B1 (en) | Marker For Diagnosing Diabetic Retinopathy and Use Thereof | |
JP7173495B2 (en) | A mass spectrometry-based method for detecting circulating histones H3 and H2B in plasma from patients with sepsis or septic shock (SS) | |
US20150212100A1 (en) | Apolipoprotein ciii in pre- and type 2 diabetes | |
TWI808975B (en) | Methods for absolute quantification of low-abundance polypeptides using mass spectrometry | |
Yang et al. | An alpha‐synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression | |
Abid et al. | Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome | |
KR101343286B1 (en) | Markers for Early Diagnosing of Diabetic Retinopathy and Use Thereof | |
WO2006108051A2 (en) | Compositions and methods relating to alzheimer's disease | |
US20240175879A1 (en) | Method for assessing efficacy of treatment protocols for neurodegenerative diseases | |
WO2024051937A1 (en) | Method for assessing efficacy of treatment protocols for neurodegenerative diseases | |
Sogawa et al. | A search for novel markers of alcohol abuse using magnetic beads and MALDI‐TOF/TOF mass spectrometry | |
EP4305426A1 (en) | Method for assessing efficacy of treatment protocols for neurodegenerative diseases | |
Yin et al. | Analysis of the peptides detected in atopic dermatitis and various inflammatory diseases patients-derived sera | |
KR101343285B1 (en) | Markers for Early Diagnosing of Diabetic Retinopathy and Use Thereof | |
EP2451465B1 (en) | Phenotypic ratio of serum amyloid in pre- and type 2 diabetes | |
KR101343137B1 (en) | Markers for Early Diagnosing of Diabetic Retinopathy and Use Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22768862 Country of ref document: EP Kind code of ref document: A1 |